{"content":"<li class=\"n-box-item date-title\" data-end=\"1483678799\" data-start=\"1483592400\" data-txt=\"Sunday, December 22, 2019\">Thursday, January  5, 2017</li><li class=\"n-box-item sa-box-item\" data-id=\"3233791\" data-ts=\"1483660725\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HELE\" target=\"_blank\">HELE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233791-helen-of-troyplus-4-on-earnings-beat-upsized-fy-2017-earnings-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Helen of Troy +4% on earnings beat, upsized FY 2017 earnings guidance</a></h4><ul><li>Helen of Troy (NASDAQ:<a href='https://seekingalpha.com/symbol/HELE' title='Helen of Troy Limited'>HELE</a>) <font color='green'>+4.2%</font>&nbsp;AH following a big <a href=\"https://seekingalpha.com/news/3233753-helen-troy-beats-0_47-misses-revenue\" target=\"_blank\">FQ3 earnings</a> beat and in-line revenues, while raising FY 2017 earnings above analyst consensus.</li><li>HELE raises its 2017 EPS outlook to $6.20-$6.50 from a previous $5.85-$6.35 vs. $6.14 analyst consensus estimate, but lowers its revenue forecast to $1.52B-$1.55B from $1.55B-$1.59B vs.  $1.55B consensus to \"reflect the expectation that the cough/cold/flu season will  remain below average and the unfavorable currency environment will  remain at current levels.\"</li><li>HELE says FQ3 gross profit margin gained 2.7 percentage points to 43.7% vs. 41% for the same period last year.</li></ul><div class=\"tiny-share-widget\" data-id=\"3233791\" data-linked=\"Helen of Troy +4% on earnings beat, upsized FY 2017 earnings guidance\" data-tweet=\"$HELE - Helen of Troy +4% on earnings beat, upsized FY 2017 earnings guidance https://seekingalpha.com/news/3233791-helen-of-troyplus-4-on-earnings-beat-upsized-fy-2017-earnings-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3233791-helen-of-troyplus-4-on-earnings-beat-upsized-fy-2017-earnings-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:58 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233789\" data-ts=\"1483658583\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMGN\" target=\"_blank\">AMGN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233789-amgen-wins-judges-ban-on-regeneron-cholesterol-drug\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Amgen wins judge&#39;s ban on Regeneron cholesterol drug</a></h4><ul><li>Amgen (NASDAQ:<a href='https://seekingalpha.com/symbol/AMGN' title='Amgen Inc.'>AMGN</a>) <font color='green'>+4.4%</font>&nbsp;AH after a federal judge said Regeneron (NASDAQ:<a href='https://seekingalpha.com/symbol/REGN' title='Regeneron Pharmaceuticals, Inc.'>REGN</a>) had to <a href=\"http://www.marketwatch.com/story/amgen-shares-soar-as-judge-blocks-sales-of-regeneron-drug-2017-01-05\" target=\"_blank\">pull its competing cholesterol  drug off the market</a> as a penalty in a patent lawsuit; REGN shares are halted.</li><li>The judge's decision blocks sales of  REGN's Praluent cholesterol treatment, stating that \"irreparable  harm\" had been done to AMGN's Repatha.</li><li><strong>Update</strong>: In a <a href=\"https://seekingalpha.com/pr/16707138-regeneron-sanofi-appeal-u-s-district-court-rulings-ongoing-patent-litigation-regarding\" target=\"_blank\">statement</a>, Regeneron and Sanofi (NASDAQ:<a href='https://seekingalpha.com/symbol/SNY' title='Sanofi'>SNY</a>) announce that they will appeal the injunction and the jury verdict upholding the validity Amgen's patents. The court has delayed the imposition of the injunction for 30 days to allow the companies to file a motion requesting a stay of the injunction during the appeal process. Praluent continues to be commercially available at this time.</li></ul><div class=\"tiny-share-widget\" data-id=\"3233789\" data-linked=\"Amgen wins judge&#39;s ban on Regeneron cholesterol drug\" data-tweet=\"$AMGN $AMGN $REGN - Amgen wins judge&#39;s ban on Regeneron cholesterol drug https://seekingalpha.com/news/3233789-amgen-wins-judges-ban-on-regeneron-cholesterol-drug?source=tweet\" data-url=\"https://seekingalpha.com/news/3233789-amgen-wins-judges-ban-on-regeneron-cholesterol-drug\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:23 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>36&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233785\" data-ts=\"1483655937\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/STML\" target=\"_blank\">STML</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233785-stemlineplus-15-on-progress-toward-quicker-fda-approval-of-leukemia-drug\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Stemline +15% on progress toward quicker FDA approval of leukemia drug</a></h4><ul>     <li>Stemline Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/STML' title='Stemline Therapeutics'>STML</a>) <font color='green'>+15.4%</font> AH after saying the <a href=\"https://seekingalpha.com/pr/16707015-stemline-therapeutics-announces-positive-fda-meeting-agreement-expedited-pathway-full\" target=\"_blank\">FDA agreed to support</a> an expedited registration pathway for SL-401, a treatment candidate for blastic plasmacytoid dendritic  cell neoplasm, an aggressive form of leukemia which currently has no approved treatment.</li>     <li>STML says its phase 2 trial for the treatment with an additional small cohort of 8-12 patients is sufficient for full approval of a biologics license application.</li>     <li>STML plans to file the application in H2 2017; if successful, it hopes for a commercial launch in 2018.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3233785\" data-linked=\"Stemline +15% on progress toward quicker FDA approval of leukemia drug\" data-tweet=\"$STML - Stemline +15% on progress toward quicker FDA approval of leukemia drug https://seekingalpha.com/news/3233785-stemlineplus-15-on-progress-toward-quicker-fda-approval-of-leukemia-drug?source=tweet\" data-url=\"https://seekingalpha.com/news/3233785-stemlineplus-15-on-progress-toward-quicker-fda-approval-of-leukemia-drug\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:38 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233782\" data-ts=\"1483654719\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SUM\" target=\"_blank\">SUM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233782-summit-materialsminus-4_4-launches-10m-share-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Summit Materials -4.4% as it launches 10M-share offering</a></h4><ul>   <li>Summit Materials (<a href='https://seekingalpha.com/symbol/SUM' title='Summit Materials'>SUM</a> <font color='red'>-1.5%</font>) is <font color='red'>off 4.4%</font> in postmarket trade after launching an <a href=\"https://seekingalpha.com/pr/16707059-summit-materials-announces-common-stock-offering\" target=\"_blank\">offering of 10M shares</a>.</li>    <li>Underwriters will get a 30-day greenshoe option for an additional 1.5M Class A shares.</li>    <li>The company plans to use proceeds to buy 10M newly issued limited partnership units from its Summit Materials Holdings unit -- which intends to use those proceeds to acquire two materials-based companies for a combined $110M in cash.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3233782\" data-linked=\"Summit Materials -4.4% as it launches 10M-share offering\" data-tweet=\"$SUM - Summit Materials -4.4% as it launches 10M-share offering https://seekingalpha.com/news/3233782-summit-materialsminus-4_4-launches-10m-share-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3233782-summit-materialsminus-4_4-launches-10m-share-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:18 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233778\" data-ts=\"1483654479\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233778-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul><li><b>Top gainers, as of 5.25 p.m.:</b> <a href='https://seekingalpha.com/symbol/GPS' title='The Gap, Inc.'>GPS</a> <font color='green'>+7.4%</font>. <a href='https://seekingalpha.com/symbol/AMGN' title='Amgen Inc.'>AMGN</a> <font color='green'>+5.2%</font>. <a href='https://seekingalpha.com/symbol/NBIX' title='Neurocrine Biosciences, Inc.'>NBIX</a> <font color='green'>+6.3%</font>. <a href='https://seekingalpha.com/symbol/MNTA' title='Momenta Pharmaceuticals, Inc.'>MNTA</a> <font color='green'>+6.1%</font>. <a href='https://seekingalpha.com/symbol/HELE' title='Helen of Troy Limited'>HELE</a> <font color='green'>+4.3%</font>.</li><li><b>Top losers, as of 5.25p.m.:</b> <a href='https://seekingalpha.com/symbol/RT' title='Ruby Tuesday, Inc.'>RT</a> <font color='red'>-17.6%</font>. <a href='https://seekingalpha.com/symbol/GIII' title='G-III Apparel Group, LTD.'>GIII</a> <font color='red'>-8.4%</font>. <a href='https://seekingalpha.com/symbol/SUM' title='Summit Materials'>SUM</a> <font color='red'>-5.6%</font>. CSAL <font color='red'>-5.5%</font>. <a href='https://seekingalpha.com/symbol/HAS' title='Hasbro, Inc.'>HAS</a> <font color='red'>-1.4%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3233778\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$GPS $AMGN $NBIX - After Hours Gainers / Losers https://seekingalpha.com/news/3233778-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3233778-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:14 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233776\" data-ts=\"1483653337\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/P\" target=\"_blank\">P</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233776-pandoraminus-3_2-sirius-cfo-dampens-takeover-talk\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pandora -3.2% as Sirius CFO dampens takeover talk</a></h4><ul>   <li>Pandora Media (NYSE:<a href='https://seekingalpha.com/symbol/P' title='Pandora Media'>P</a>) shares have <font color='red'>fallen 3.2%</font> in postmarket trading after a Sirius XM (<a href='https://seekingalpha.com/symbol/SIRI' title='Sirius XM Holdings Inc.'>SIRI</a> <font color='green'>+2.4%</font>) exec dampened speculation about M&amp;A as \"not very likely.\"</li>    <li>Shares had gained in December amid increasing chatter about a tie-up. That followed summer reports that Liberty Global had floated a $15/share offer that <a href=\"https://seekingalpha.com/news/3194850-wsj-liberty-floated-15-share-offer-pandora-combine-sirius-xm\" target=\"_blank\">looked like it was rebuffed</a>, and comments from Liberty chief Greg Maffei that any streaming buy would be <a href=\"https://seekingalpha.com/news/3200805-libertys-maffei-streaming-buy-linked-sirius-xm\" target=\"_blank\">linked to Sirius XM</a>.</li>    <li>Speaking at a Citigroup conference, Sirius XM Chief Financial Officer David Frear says despite all that, \"I have doubts\" about Pandora's strategy and isn't sure about cross-selling opportunities.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3233776\" data-linked=\"Pandora -3.2% as Sirius CFO dampens takeover talk\" data-tweet=\"$P $P $SIRI - Pandora -3.2% as Sirius CFO dampens takeover talk https://seekingalpha.com/news/3233776-pandoraminus-3_2-sirius-cfo-dampens-takeover-talk?source=tweet\" data-url=\"https://seekingalpha.com/news/3233776-pandoraminus-3_2-sirius-cfo-dampens-takeover-talk\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:55 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>73&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233772\" data-ts=\"1483652800\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMRN\" target=\"_blank\">AMRN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233772-amarin-sees-2017-top-line-155m-165m-shares-up-1-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Amarin sees 2017 top line between $155M - 165M; shares up 1% after hours</a></h4><ul><li>In a <a href=\"https://seekingalpha.com/pr/16706905-amarin-provides-preliminary-2016-results-2017-outlook\" target=\"_blank\">update </a>to investors ahead of next weeks presentation at JPM17, Amarin (NASDAQ:<a href='https://seekingalpha.com/symbol/AMRN' title='Amarin Corporation PLC'>AMRN</a>) says 2016 revenue should be slightly above $125M (+54%), expected to grow as much as 32% this year to as high as $165M. Vascepa prescriptions rose more than 50% and represented more than 20% of the prescription omega-3 market.</li><li>The large-scale cardiovascular outcomes trial, REDUCE-IT, has one more year to run. Top-line data are expected in 2018.</li><li>Cash balance was ~$98M at the end of 2016.</li><li>#JPM17</li></ul><div class=\"tiny-share-widget\" data-id=\"3233772\" data-linked=\"Amarin sees 2017 top line between $155M - 165M; shares up 1% after hours\" data-tweet=\"$AMRN - Amarin sees 2017 top line between $155M - 165M; shares up 1% after hours https://seekingalpha.com/news/3233772-amarin-sees-2017-top-line-155m-165m-shares-up-1-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3233772-amarin-sees-2017-top-line-155m-165m-shares-up-1-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:46 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233768\" data-ts=\"1483651749\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MRTX\" target=\"_blank\">MRTX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233768-mirati-readies-equity-offering-shares-ease-8-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mirati readies equity offering; shares ease 8% after hours</a></h4><ul><li>Mirati Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/MRTX' title='Mirati Therapeutics, Inc.'>MRTX</a>) <a href=\"https://seekingalpha.com/pr/16706889-mirati-therapeutics-announces-proposed-public-offering-common-stock\" target=\"_blank\">initiates </a>a public offering of common stock. Price, volume and terms have yet to be announced. Shares are down&nbsp;<font color='red'>8%</font>&nbsp;after hours on modest volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3233768\" data-linked=\"Mirati readies equity offering; shares ease 8% after hours\" data-tweet=\"$MRTX - Mirati readies equity offering; shares ease 8% after hours https://seekingalpha.com/news/3233768-mirati-readies-equity-offering-shares-ease-8-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3233768-mirati-readies-equity-offering-shares-ease-8-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:29 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233765\" data-ts=\"1483651306\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GPS\" target=\"_blank\">GPS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233765-gap-up-12-december-store-sales-rise-4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gap up 12% as December same-store sales rise 4%</a></h4><ul>     <li>Gap Inc. (<a href='https://seekingalpha.com/symbol/GPS' title='The Gap, Inc.'>GPS</a> <font color='red'>-4%</font>) has <font color='green'>jumped 11.8%</font> after hours after its <a href=\"https://seekingalpha.com/pr/16706972-gap-inc-reports-holiday-sales-results\" target=\"_blank\">holiday sales beat some middling expectations</a>, with net sales up 1% and comparable sales up 2% for the November-December holiday season.</li>     <li>For December, net sales rose 3% to $2.07B, and comparable sales rose 4% (vs. last year's 5% decrease).</li>   <li>December comp sales by brand: Gap Global, +1% (vs. -2% last year); Banana Republic Global, -7% (vs. -9%); Old Navy Global, +12% (vs. -7%).</li>     <li>Based on the results, the company says it now sees full-year EPS \"modestly above the high end\" of a previously adjusted guidance for $1.92.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3233765\" data-linked=\"Gap up 12% as December same-store sales rise 4%\" data-tweet=\"$GPS - Gap up 12% as December same-store sales rise 4% https://seekingalpha.com/news/3233765-gap-up-12-december-store-sales-rise-4?source=tweet\" data-url=\"https://seekingalpha.com/news/3233765-gap-up-12-december-store-sales-rise-4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:21 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233762\" data-ts=\"1483651020\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FRSH\" target=\"_blank\">FRSH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233762-papa-murphys-ceo-calwell-resigns-birch-named-interim-ceo\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Papa Murphy&#39;s CEO Calwell resigns, Birch named interim CEO</a></h4><ul>     <li>Papa Murphy's (NASDAQ:<a href='https://seekingalpha.com/symbol/FRSH' title='Papa Murphy&#39;s Holdings, Inc.'>FRSH</a>) <font color='red'>-2.4%</font>&nbsp;AH after Ken Calwell <a href=\"https://seekingalpha.com/pr/16706935-papa-murphy-s-holdings-inc-announces-senior-management-change\" target=\"_blank\">resigns</a> as CEO to pursue other interests, and Chairman Jean Birch is appointed interim CEO.</li>     <li>Birch has served as Chair since September and as a board member since April 2015; she has 26 years of restaurant leadership experience, previously serving as president of IHOP Restaurants, Romano&rsquo;s Macaroni Grill and Corner Bakery Cafe.</li>     <li>Calwell was CEO of FRSH since December 2011, after serving three years as Chief Marketing Officer and Chief Food Innovation Officer of Wendy&rsquo;s and eight years in various roles at Domino&rsquo;s Pizza.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3233762\" data-linked=\"Papa Murphy&#39;s CEO Calwell resigns, Birch named interim CEO\" data-tweet=\"$FRSH - Papa Murphy&#39;s CEO Calwell resigns, Birch named interim CEO https://seekingalpha.com/news/3233762-papa-murphys-ceo-calwell-resigns-birch-named-interim-ceo?source=tweet\" data-url=\"https://seekingalpha.com/news/3233762-papa-murphys-ceo-calwell-resigns-birch-named-interim-ceo\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:17 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233759\" data-ts=\"1483650798\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LOXO\" target=\"_blank\">LOXO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233759-loxo-oncology-prices-stock-offering-31\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Loxo Oncology prices stock offering at $31</a></h4><ul><li>Loxo Oncology (NASDAQ:<a href='https://seekingalpha.com/symbol/LOXO' title='Loxo Oncology'>LOXO</a>) <a href=\"https://www.sec.gov/Archives/edgar/data/1581720/000110465917000903/a17-1272_3ex99d1.htm\" target=\"_blank\">prices </a>its public offering of 3.87M shares of common stock at $31. Underwriters over-allotment is an additional 580.5K shares. Closing date is January 10.</li><li>Net proceeds will fund early commercialization activities for larotrectinib, R&amp;D and general corporate purposes.</li><li>Today's close was $33.26.</li></ul><div class=\"tiny-share-widget\" data-id=\"3233759\" data-linked=\"Loxo Oncology prices stock offering at $31\" data-tweet=\"$LOXO - Loxo Oncology prices stock offering at $31 https://seekingalpha.com/news/3233759-loxo-oncology-prices-stock-offering-31?source=tweet\" data-url=\"https://seekingalpha.com/news/3233759-loxo-oncology-prices-stock-offering-31\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:13 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233746\" data-ts=\"1483648758\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DISH\" target=\"_blank\">DISH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233746-t-mobile-simplifying-to-one-unlimited-plan-offers-data-rebate-feature\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">T-Mobile simplifying to one unlimited plan; offers data rebate feature</a></h4><ul>   <li>At its \"Un-carrier Next\" event, T-Mobile (<a href='https://seekingalpha.com/symbol/TMUS' title='T-Mobile US, Inc.'>TMUS</a> <font color='red'>-2%</font>) revealed that it will market and sell just one unlimited plan starting Jan. 22.</li>    <li>The T-Mobile One All-In plan will roll taxes and fees together so the plan is sold at one price that's not planned to change.</li>    <li>Despite the unlimited-data nature, T-Mobile is also offering a \"KickBack\" feature that pays back to lightly-used data plans. Lines that don't use more than 2 GB of data in a month will get up to $10 in bill credit on the next month's bill -- a major-provider move not dissimilar to the \"buy-what-you-use\" plans at Google's Project Fi.</li>    <li>In a series of New Year prognostications, Legere predicted Dish Network (<a href='https://seekingalpha.com/symbol/DISH' title='DISH Network Corporation'>DISH</a> <font color='green'>+0.9%</font>) would \"die\" this year (possibly via merger) and that three of the four wireless chiefs would change during the year. He had little to say about a Sprint (NYSE:<a href='https://seekingalpha.com/symbol/S' title='Sprint Corporation'>S</a>)&nbsp;merger but \"It's pretty clear that Sprint needs to do something ... Sprint themselves is like an 'exploding plan' \" (referring to promotional wireless plans).</li><li>He added that \"two of the most hated companies in the world\" will talk about coming together as \"the ultimate evil corporation of all time.\"</li>    <li>\"Vericast or Comizon, I don't know,\" Legere said (VZ, CMCSA). \"If you combine the two most hated companies in America, you get the No. 1 most hated company,\" he added. \"Talk about synergies.\"</li> </ul><div class=\"tiny-share-widget\" data-id=\"3233746\" data-linked=\"T-Mobile simplifying to one unlimited plan; offers data rebate feature\" data-tweet=\"$DISH $DISH $S - T-Mobile simplifying to one unlimited plan; offers data rebate feature https://seekingalpha.com/news/3233746-t-mobile-simplifying-to-one-unlimited-plan-offers-data-rebate-feature?source=tweet\" data-url=\"https://seekingalpha.com/news/3233746-t-mobile-simplifying-to-one-unlimited-plan-offers-data-rebate-feature\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:39 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>50&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233744\" data-ts=\"1483648360\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233744-gold-moves-to-5-week-high-on-soft-data-falling-rates\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gold moves to 5-week high on soft data, falling rates</a></h4><ul><li>A&nbsp;<font color='green'>1.35% advance</font>&nbsp;today brings gold back to $1,181 per ounce, its highest level since early December.</li><li>The major averages are holding up fine this week, but interest rates have declined in the new year amid some soft economic numbers and lousy numbers from retailers. The XRT is&nbsp;<font color='red'>down 2.3%&nbsp;</font>today and the XLF&nbsp;<font color='red'>down 1.2%</font>.</li><li><a href='https://seekingalpha.com/symbol/GLD' title='SPDR Gold Trust ETF'>GLD</a>&nbsp;<font color='green'>+1.5%</font></li><li>ETFs: <a href='https://seekingalpha.com/symbol/GLD' title='SPDR Gold Trust ETF'>GLD</a>, <a href='https://seekingalpha.com/symbol/IAU' title='iShares Gold Trust ETF'>IAU</a>, <a href='https://seekingalpha.com/symbol/PHYS' title='Sprott Physical Gold Trust'>PHYS</a>, <a href='https://seekingalpha.com/symbol/SGOL' title='ETFS Physical Swiss Gold Trust ETF'>SGOL</a>, <a href='https://seekingalpha.com/symbol/UGL' title='ProShares Ultra Gold ETF'>UGL</a>, <a href='https://seekingalpha.com/symbol/DGP' title='DB Gold Double Long ETN'>DGP</a>, <a href='https://seekingalpha.com/symbol/GTU' title='Central Gold-Trust'>GTU</a>, <a href='https://seekingalpha.com/symbol/UGLD' title='VelocityShares 3x Long Gold ETN'>UGLD</a>, <a href='https://seekingalpha.com/symbol/GLL' title='ProShares UltraShort Gold ETF'>GLL</a>, <a href='https://seekingalpha.com/symbol/DZZ' title='DB Gold Double Short ETN'>DZZ</a>, <a href='https://seekingalpha.com/symbol/GLDI' title='Credit Suisse Gold Shares Covered Call ETN'>GLDI</a>, <a href='https://seekingalpha.com/symbol/OUNZ' title='VanEck Merk Gold Trust ETF'>OUNZ</a>, <a href='https://seekingalpha.com/symbol/DGL' title='PowerShares DB Gold ETF'>DGL</a>, <a href='https://seekingalpha.com/symbol/DGZ' title='DB Gold Short ETN'>DGZ</a>, <a href='https://seekingalpha.com/symbol/DGLD' title='VelocityShares 3x Inverse Gold ETN'>DGLD</a>, <a href='https://seekingalpha.com/symbol/GYEN' title='AdvisorShares Gartman Gold/Yen ETF'>GYEN</a>, <a href='https://seekingalpha.com/symbol/GEUR' title='AdvisorShares Gartman Gold/Euro ETF'>GEUR</a>, <a href='https://seekingalpha.com/symbol/UBG' title='UBS ETRACS CMCI Gold Total Return ETN'>UBG</a>, <a href='https://seekingalpha.com/symbol/QGLDX' title='The Gold Bullion Strategy Fund Inv'>QGLDX</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3233744\" data-linked=\"Gold moves to 5-week high on soft data, falling rates\" data-tweet=\"$GLD $IAU $PHYS - Gold moves to 5-week high on soft data, falling rates https://seekingalpha.com/news/3233744-gold-moves-to-5-week-high-on-soft-data-falling-rates?source=tweet\" data-url=\"https://seekingalpha.com/news/3233744-gold-moves-to-5-week-high-on-soft-data-falling-rates\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:32 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233742\" data-ts=\"1483647143\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EGY\" target=\"_blank\">EGY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233742-vaalco-energy-well-back-in-production-after-pump-failure\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Vaalco Energy well back in production after pump failure</a></h4><ul>     <li>Vaalco Energy (<a href='https://seekingalpha.com/symbol/EGY' title='VAALCO Energy, Inc.'>EGY</a> <font color='green'>+13.8%</font>) surges after announcing the Avouma 2-H well offshore Gabon has <a href=\"https://seekingalpha.com/pr/16705771-vaalco-energy-announces-successful-workover-avouma-2-h-well-now-producing-2700-barrels-oil\" target=\"_blank\">returned to  production</a> after utilizing a hydraulic  workover unit to replace a failed electric submersible pump.</li>     <li>EGY says the  well is producing at a stabilized rate of 2,700 gross bbl/day of oil, or 730 bbl/day net to the company; with the addition of two recent  workover wells, total company net production now averages 4,600 bbl/day.</li>     <li>EGY has endured problems with electrical submersible pumps in recent months, causing failures at the Avouma 2-H and South Tchibala 2-H wells.</li></ul><div class=\"tiny-share-widget\" data-id=\"3233742\" data-linked=\"Vaalco Energy well back in production after pump failure\" data-tweet=\"$EGY - Vaalco Energy well back in production after pump failure https://seekingalpha.com/news/3233742-vaalco-energy-well-back-in-production-after-pump-failure?source=tweet\" data-url=\"https://seekingalpha.com/news/3233742-vaalco-energy-well-back-in-production-after-pump-failure\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:12 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233739\" data-ts=\"1483646496\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233739-technology-top-gainers-losers-of-3-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top Gainers / Losers as of 3:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/HEAR' title='Turtle Beach Corporation'>HEAR</a> <font color='green'>+20%</font>. <a href='https://seekingalpha.com/symbol/QTNA' title='Quantenna Communications'>QTNA</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/CYBE' title='CyberOptics Corporation'>CYBE</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/CBAK-OLD' title='China BAK Battery, Inc.'>CBAK-OLD</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/CALL' title='magicJack VocalTec Communications Ltd.'>CALL</a> <font color='green'>+10%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/CSLT' title='Castlight Health, Inc.'>CSLT</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/IT' title='Gartner Inc.'>IT</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/GSAT' title='Globalstar, Inc.'>GSAT</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/ZAYO' title='Zayo Group'>ZAYO</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/COVS' title='Covisint Corporation'>COVS</a> <font color='red'>-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3233739\" data-linked=\"Technology - Top Gainers / Losers as of 3:00 pm\" data-tweet=\"$HEAR $QTNA $CYBE - Technology - Top Gainers / Losers as of 3:00 pm https://seekingalpha.com/news/3233739-technology-top-gainers-losers-of-3-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3233739-technology-top-gainers-losers-of-3-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233741\" data-ts=\"1483646319\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TMUS\" target=\"_blank\">TMUS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233741-t-mobile-reports-2_1m-net-customer-additions-in-q4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">T-Mobile reports 2.1M net customer additions in Q4</a></h4><ul>   <li>Previewing its Q4 ahead of its latest \"Un-carrier\" announcement, T-Mobile (<a href='https://seekingalpha.com/symbol/TMUS' title='T-Mobile US, Inc.'>TMUS</a> <font color='red'>-1.7%</font>) says it <a href=\"https://seekingalpha.com/pr/16706788-t-mobile-delivers-strong-customer-growth\" target=\"_blank\">added 2.1M net customers</a> (1.2M branded postpaid) and 541,000 branded prepaid net adds.</li>    <li>That marks the 15th straight quarter of 1M-plus additions, and led the company to post 8.2M total net adds for the year (the third straight year of 8M-plus).</li>    <li>The numbers bring total customer count to 71.5M at year-end, T-Mobile says.</li>    <li>In Q4, the company posted branded postpaid phone churn of 1.28% (down 18 basis points). Branded prepaid churn fell 26 bps Y/Y to 3.94%, best ever for a Q4.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3233741\" data-linked=\"T-Mobile reports 2.1M net customer additions in Q4\" data-tweet=\"$TMUS - T-Mobile reports 2.1M net customer additions in Q4 https://seekingalpha.com/news/3233741-t-mobile-reports-2_1m-net-customer-additions-in-q4?source=tweet\" data-url=\"https://seekingalpha.com/news/3233741-t-mobile-reports-2_1m-net-customer-additions-in-q4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:58 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233736\" data-ts=\"1483644505\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MDP\" target=\"_blank\">MDP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233736-time-inc-jumps-on-chatter-potential-meredith-merger\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Time Inc. jumps on chatter about potential Meredith merger</a></h4><ul>   <li>Time Inc. (TIME) has spiked, <font color='green'>up 3.5%</font>, on a Bloomberg report that the company was contacted by lifestyle publisher Meredith (NYSE:<a href='https://seekingalpha.com/symbol/MDP' title='Meredith Corporation'>MDP</a>) about the prospect of a merger.</li>    <li>Meredith shares, <font color='red'>down as much as 3%</font> earlier, have gotten a lift and are <font color='red'>down just 1.7%</font> now.</li>    <li>Time hasn't discouraged talk about mergers; it <a href=\"https://seekingalpha.com/news/3229507-time-plus-7-percent-hiring-bankers-discuss-buyout-offers\" target=\"_blank\">hired bankers</a> to talk about buyout offers in early December (after receiving overtures from a group led by Edgar Bronfman Jr.), and CEO Rich Battista's holiday memo told staffers <a href=\"https://seekingalpha.com/news/3231222-time-chiefs-holiday-memo-surprised-m-chatter\" target=\"_blank\">not to be surprised</a> by heavy merger talk.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3233736\" data-linked=\"Time Inc. jumps on chatter about potential Meredith merger\" data-tweet=\"$MDP - Time Inc. jumps on chatter about potential Meredith merger https://seekingalpha.com/news/3233736-time-inc-jumps-on-chatter-potential-meredith-merger?source=tweet\" data-url=\"https://seekingalpha.com/news/3233736-time-inc-jumps-on-chatter-potential-meredith-merger\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:28 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233731\" data-ts=\"1483643857\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AIRB\" target=\"_blank\">AIRB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233731-rough-session-for-lodging-reits-on-sell-side-caution\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Rough session for lodging REITs on sell-side caution</a></h4><ul><li>The dollar's having one of its worst session in weeks if not months, interest rates are falling, and the broad equity REITs are higher, but the hotel REITs are down sharply nearly across the board.</li><li>Noting outsized supply growth in the top 25 U.S. markets, JPMorgan's Joseph Greff says the lodging names \"don't represent value.\"</li><li>DA Davidson's Ryan Meliker says the stocks \"no longer screen attractively\" after their big bounce higher this year.</li><li>Airbnb (<a href='https://seekingalpha.com/symbol/AIRB' title='Airbnb, Inc.'>AIRB</a>) is the \"$30B elephant in the room,\" says Macquarie's Chad Beynon. If strong growth at the startup continues, it should \"visibly\" impact hotels.</li><li>Hospitality Properties Trust (<a href='https://seekingalpha.com/symbol/HPT' title='Hospitality Properties Trust'>HPT</a> <font color='red'>-2.6%</font>), Sunstone Hotel (<a href='https://seekingalpha.com/symbol/SHO' title='Sunstone Hotel Investors, Inc.'>SHO</a> <font color='red'>-3.7%</font>), LaSalle Hotel (<a href='https://seekingalpha.com/symbol/LHO' title='LaSalle Hotel Properties'>LHO</a> <font color='red'>-3.3%</font>), Pebblebrook Hotel (<a href='https://seekingalpha.com/symbol/PEB' title='Pebblebrook Hotel Trust'>PEB</a> <font color='red'>-4.2%</font>), Chesapeake Lodging (<a href='https://seekingalpha.com/symbol/CHSP' title='Chesapeake Lodging Trust'>CHSP</a> <font color='red'>-1.7%</font>), Summit Hotel (<a href='https://seekingalpha.com/symbol/INN' title='Summit Hotel Properties, Inc.'>INN</a> <font color='red'>-1.7%</font>), Apple Hospitality (<a href='https://seekingalpha.com/symbol/APLE' title='Apple Hospitality REIT, Inc.'>APLE</a> <font color='red'>-1%</font>), DiamondRock Hospitality (<a href='https://seekingalpha.com/symbol/DRH' title='DiamondRock Hospitality Company'>DRH</a> <font color='red'>-2.7%</font>), Host Hotel (<a href='https://seekingalpha.com/symbol/HT' title='Hersha Hospitality Trust'>HT</a> <font color='red'>-1.4%</font>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3233731\" data-linked=\"Rough session for lodging REITs on sell-side caution\" data-tweet=\"$AIRB $AIRB $SVC - Rough session for lodging REITs on sell-side caution https://seekingalpha.com/news/3233731-rough-session-for-lodging-reits-on-sell-side-caution?source=tweet\" data-url=\"https://seekingalpha.com/news/3233731-rough-session-for-lodging-reits-on-sell-side-caution\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:17 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233729\" data-ts=\"1483643244\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VIA\" target=\"_blank\">VIA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233729-viacom-shaking-up-leadership-ranks-cable-execs-to-be-cut\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Viacom shaking up leadership ranks; cable execs to be cut</a></h4><ul>   <li>Viacom (<a href='https://seekingalpha.com/symbol/VIA' title='Viacom Inc.'>VIA</a> <font color='green'>+1.5%</font>, <a href='https://seekingalpha.com/symbol/VIAB' title='Viacom Inc.'>VIAB</a> <font color='green'>+2.3%</font>) is beginning a bit of a leadership shakeup at the behest of newly installed CEO Bob Bakish.</li>    <li>He's <a href=\"http://variety.com/2017/tv/news/viacom-sarah-levy-promotion-coo-global-entertainment-group-1201953273/\" target=\"_blank\">named Sarah Levy</a>, an 18-year veteran, to lead domestic and international cable operations, and will look to trim ranks in other groups.</li>    <li>Levy most recently has been chief operating officer at Viacom's Kids and Family Group (which includes Nickelodeon). She'll take over that COO title at Viacom's Global Entertainment Group, newly created late last year to combine international with music and entertainment, along with TV Land and CMT.</li>    <li>The company is set to <a href=\"http://www.reuters.com/article/us-viacom-reorg-idUSKBN14P23W\" target=\"_blank\">cut executives in the music and entertainment group</a> after veteran Doug Herzog's departure this week. That group covers the company's cable nets, including Comedy Central and MTV.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3233729\" data-linked=\"Viacom shaking up leadership ranks; cable execs to be cut\" data-tweet=\"$VIA $VIA $VIAB - Viacom shaking up leadership ranks; cable execs to be cut https://seekingalpha.com/news/3233729-viacom-shaking-up-leadership-ranks-cable-execs-to-be-cut?source=tweet\" data-url=\"https://seekingalpha.com/news/3233729-viacom-shaking-up-leadership-ranks-cable-execs-to-be-cut\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:07 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233727\" data-ts=\"1483642895\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233727-energy-materials-top-5-gainers-losers-of-2-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top 5 Gainers / Losers as of 2:00 pm</a></h4><ul> <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/BCEI' title='Bonanza Creek Energy'>BCEI</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/EGY' title='VAALCO Energy, Inc.'>EGY</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/AXU' title='Alexco Resource Corporation'>AXU</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/CDE' title='Coeur Mining, Inc.'>CDE</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/AGI' title='Alamos Gold Inc'>AGI</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/RIC' title='Richmont Mines, Inc'>RIC</a> <font color='green'>+11%</font>.</li> <li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/CGG-OLD' title='CGG'>CGG-OLD</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/LEU' title='Centrus Energy Corp.'>LEU</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/ESES' title='Eco-Stim Energy Solutions, Inc.'>ESES</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/HLX' title='Helix Energy Solutions Group, Inc.'>HLX</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/PBF' title='PBF Energy'>PBF</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/SCHN' title='Schnitzer Steel Industries, Inc.'>SCHN</a> <font color='red'>-6%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3233727\" data-linked=\"Energy/Materials - Top 5 Gainers / Losers as of 2:00 pm\" data-tweet=\"$BCEI $EGY $AXU - Energy/Materials - Top 5 Gainers / Losers as of 2:00 pm https://seekingalpha.com/news/3233727-energy-materials-top-5-gainers-losers-of-2-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3233727-energy-materials-top-5-gainers-losers-of-2-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233723\" data-ts=\"1483642158\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PANW\" target=\"_blank\">PANW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233723-citron-research-issues-bullish-note-on-palo-alto-networks\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Citron Research issues bullish note on Palo Alto Networks</a></h4><ul><li>Amid a <a href=\"http://www.nytimes.com/2017/01/05/us/politics/armed-services-committee-john-mccain-russia-hacking.html?_r=0\" target=\"_blank\">U.S. Senate Armed Services Committee</a> hearing involving address of various points on cybersecurity, <a href=\"https://twitter.com/CitronResearch/status/817071165088874497\" target=\"_blank\">Citron Research notes confidence</a> in Palo Alto Networks for 2017 and considers cybersecurity \"one of the best secular stories in technology.\"</li><li>Spotlights Palo Alto Networks'&nbsp;<a href=\"https://www.paloaltonetworks.com/technologies/single-pass-architecture\" target=\"_blank\">\"Single-Pass Architecture,\"</a> market growth, network effect (more value per customer added), competitive edge, 75%+ gross margins and growing, appeal on a cash flow basis, entry into a fresh upgrade/replace/refresh cycle and increasingly shareholder-friendly management.</li><li>Shares (NYSE:<a href='https://seekingalpha.com/symbol/PANW' title='Palo Alto Networks'>PANW</a>)&nbsp;<font color='green'>+4.04%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3233723\" data-linked=\"Citron Research issues bullish note on Palo Alto Networks\" data-tweet=\"$PANW - Citron Research issues bullish note on Palo Alto Networks https://seekingalpha.com/news/3233723-citron-research-issues-bullish-note-on-palo-alto-networks?source=tweet\" data-url=\"https://seekingalpha.com/news/3233723-citron-research-issues-bullish-note-on-palo-alto-networks\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:49 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233722\" data-ts=\"1483642154\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TWX\" target=\"_blank\">TWX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233722-time-warnerminus-2-and-t-dips-trump-reportedly-still-against-merger\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Time Warner -2%, AT&amp;T dips as Trump reportedly still against merger</a></h4><ul>     <li>Time Warner (NYSE:<a href='https://seekingalpha.com/symbol/TWX' title='Time Warner Inc.'>TWX</a>) takes a dip, <font color='red'>down 2%</font> after trading around the flat line today, on chatter from Bloomberg that President-elect Donald Trump told a confidant he's still against the company's $85B acquisition deal with AT&amp;T (NYSE:<a href='https://seekingalpha.com/symbol/T' title='AT&T Inc.'>T</a>).</li>   <li>After months of silence, Trump reportedly told a friend he still thinks the merger is a bad deal because he thinks it would concentrate too much power, according to a leak.</li>     <li>AT&amp;T's taken its own leg down, <font color='red'>-0.4%</font> from positive ground.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3233722\" data-linked=\"Time Warner -2%, AT&amp;T dips as Trump reportedly still against merger\" data-tweet=\"$TWX $TWX $T - Time Warner -2%, AT&amp;T dips as Trump reportedly still against merger https://seekingalpha.com/news/3233722-time-warnerminus-2-and-t-dips-trump-reportedly-still-against-merger?source=tweet\" data-url=\"https://seekingalpha.com/news/3233722-time-warnerminus-2-and-t-dips-trump-reportedly-still-against-merger\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:49 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>63&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233720\" data-ts=\"1483641528\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VZ\" target=\"_blank\">VZ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233720-verizon-exec-company-unsure-yahoo-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Verizon exec: Company &#39;unsure&#39; about Yahoo deal</a></h4><ul>   <li>Verizon (<a href='https://seekingalpha.com/symbol/VZ' title='Verizon Communications'>VZ</a> <font color='green'>+0.1%</font>) executive Marni Walden didn't move much from a previous stance on her company's deal to acquire the core Internet business of Yahoo (<a href=\"https://seekingalpha.com/symbol/YHOO\" target=\"_blank\">YHOO</a> <font color='green'>+2.9%</font>), characterizing Verizon as <a href=\"http://www.reuters.com/article/us-yahoo-m-a-verizon-idUSKBN14P215\" target=\"_blank\">\"unsure\" about the deal</a>.</li>    <li>Speaking at Citi's Internet, Media and Telecommunications Conference, Walden said \"I can't sit here today and say with confidence one way or another because we still don't know.\"</li>    <li>That puts some outsize importance on the revelations of two massive data breaches at Yahoo, since she says the merits of the deal still make sense (a <a href=\"https://seekingalpha.com/news/3216940-verizon-exec-yahoo-deal-still-makes-sense-despite-security-breach\" target=\"_blank\">stance she had taken</a> at a <i>WSJ</i> conference in October). On Oct. 26, she said \"We're hoping that in the next 60 days or less that we can have an outcome.\"</li> </ul><div class=\"tiny-share-widget\" data-id=\"3233720\" data-linked=\"Verizon exec: Company &#39;unsure&#39; about Yahoo deal\" data-tweet=\"$VZ $VZ $AABA - Verizon exec: Company &#39;unsure&#39; about Yahoo deal https://seekingalpha.com/news/3233720-verizon-exec-company-unsure-yahoo-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3233720-verizon-exec-company-unsure-yahoo-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:38 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>21&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233719\" data-ts=\"1483641458\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TWTR\" target=\"_blank\">TWTR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233719-chatter-dorsey-exit-twitter-rising-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Chatter about Dorsey exit has Twitter rising 2%</a></h4><ul><li>Loose chatter that Jack Dorsey may be leaving the CEO job at Twitter (NYSE:<a href='https://seekingalpha.com/symbol/TWTR' title='Twitter, Inc.'>TWTR</a>) has the stock on the move in the last few minutes. In the red not long ago, shares are currently&nbsp;<font color='green'>higher by 1.85%</font>.</li><li><a href='https://seekingalpha.com/symbol/SQ' title='Square, Inc.'>SQ</a>&nbsp;<font color='green'>+0.9%</font></li></ul><div class=\"tiny-share-widget\" data-id=\"3233719\" data-linked=\"Chatter about Dorsey exit has Twitter rising 2%\" data-tweet=\"$TWTR $TWTR $SQ - Chatter about Dorsey exit has Twitter rising 2% https://seekingalpha.com/news/3233719-chatter-dorsey-exit-twitter-rising-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3233719-chatter-dorsey-exit-twitter-rising-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:37 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>43&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233713\" data-ts=\"1483639339\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BBY\" target=\"_blank\">BBY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233713-retail-sell-off-spreads-from-high-to-low\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Retail sell-off spreads from high to low</a></h4><ul><li>The sell-off in retail kickstarted by department store weakness has dragged some of the larger U.S. chains into its reaches and spread from luxury to discounters.</li><li>Notable decliners include Best Buy (<a href='https://seekingalpha.com/symbol/BBY' title='Best Buy Co.'>BBY</a> <font color='red'>-2.9%</font>), Target (<a href='https://seekingalpha.com/symbol/TGT' title='Target Corporation'>TGT</a> <font color='red'>-2.2%</font>), Staples (<a href='https://seekingalpha.com/symbol/SPLS' title='Staples, Inc.'>SPLS</a> <font color='red'>-1.1%</font>), Dick's Sporting Goods (<a href='https://seekingalpha.com/symbol/DKS' title='Dick&#39;s Sporting Goods, Inc.'>DKS</a> <font color='red'>-2.6%</font>), Signet Jewelers (<a href='https://seekingalpha.com/symbol/SIG' title='Signet Jewelers Limited'>SIG</a> <font color='red'>-7.9%</font>), Dollar General (<a href='https://seekingalpha.com/symbol/DG' title='Dollar General Corporation'>DG</a> <font color='red'>-2.4%</font>), Tiffany (<a href='https://seekingalpha.com/symbol/TIF' title='Tiffany & Co.'>TIF</a> <font color='red'>-3.5%</font>), Michael Kors (KORS <font color='red'>-4.6%</font>), Sally Beauty Holdings (<a href='https://seekingalpha.com/symbol/SBH' title='Sally Beauty Holdings, Inc.'>SBH</a> <font color='red'>-3.3%</font>) and The Michaels Companies (<a href='https://seekingalpha.com/symbol/MIK' title='The Michaels Companies'>MIK</a> <font color='red'>-1.8%</font>) .</li><li>ETFs: <a href='https://seekingalpha.com/symbol/XLY' title='Consumer Discretionary Select Sector SPDR ETF'>XLY</a>, <a href='https://seekingalpha.com/symbol/XRT' title='SPDR S&P Retail ETF'>XRT</a>, <a href='https://seekingalpha.com/symbol/VCR' title='Vanguard Consumer Discretionary ETF'>VCR</a>, <a href='https://seekingalpha.com/symbol/RTH' title='VanEck Vectors Retail ETF'>RTH</a>, <a href='https://seekingalpha.com/symbol/RETL' title='Direxion Daily Retail Bull 3x Shares ETF'>RETL</a>, <a href='https://seekingalpha.com/symbol/FXD' title='First Trust Consumer Discretionary AlphaDEX ETF'>FXD</a>, <a href='https://seekingalpha.com/symbol/IYC' title='iShares U.S. Consumer Services ETF'>IYC</a>, <a href='https://seekingalpha.com/symbol/FDIS' title='Fidelity MSCI Consumer Discretionary Index ETF'>FDIS</a>, <a href='https://seekingalpha.com/symbol/SCC' title='ProShares UltraShort Consumer Services ETF'>SCC</a>, <a href='https://seekingalpha.com/symbol/RCD' title='Invesco S&P Equal Weight Consumer Discretionary ETF'>RCD</a>, <a href='https://seekingalpha.com/symbol/UCC' title='ProShares Ultra Consumer Services ETF'>UCC</a>, <a href='https://seekingalpha.com/symbol/PMR' title='Invesco Dynamic Retail Portfolio ETF'>PMR</a>, <a href='https://seekingalpha.com/symbol/CNDF' title='iShares Edge MSCI Multifactor Consumer Discretionary ETF'>CNDF</a>, <a href='https://seekingalpha.com/symbol/FTXD' title='First Trust Nasdaq Retail ETF'>FTXD</a>, <a href='https://seekingalpha.com/symbol/JHMC' title='John Hancock Multifactor Consumer Discretionary ETF'>JHMC</a>.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3233670-department-stores-ground-zero-retail-shellacking\" target=\"_blank\">Department stores ground zero for retail shellacking</a> (Jan. 5)</li></ul><div class=\"tiny-share-widget\" data-id=\"3233713\" data-linked=\"Retail sell-off spreads from high to low\" data-tweet=\"$BBY $BBY $TGT - Retail sell-off spreads from high to low https://seekingalpha.com/news/3233713-retail-sell-off-spreads-from-high-to-low?source=tweet\" data-url=\"https://seekingalpha.com/news/3233713-retail-sell-off-spreads-from-high-to-low\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:02 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233708\" data-ts=\"1483639212\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233708-financials-top-5-gainers-losers-of-1-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top 5 Gainers / Losers as of 1:00 PM</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/ASA' title='ASA Gold&Precious Metals'>ASA</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/FAC' title='First Acceptance Corporation'>FAC</a> <font color='green'>+7%</font>.</li><li><b>Losers:</b> WAC <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/SIEB' title='Siebert Financial Corp.'>SIEB</a> <font color='red'>-5%</font>. <a href='https://seekingalpha.com/symbol/GHL' title='Greenhill & Co., Inc.'>GHL</a> <font color='red'>-5%</font>. <a href='https://seekingalpha.com/symbol/CACC' title='Credit Acceptance Corporation'>CACC</a> <font color='red'>-5%</font>. <a href='https://seekingalpha.com/symbol/ONDK' title='OnDeck Capital'>ONDK</a> <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3233708\" data-linked=\"Financials - Top 5 Gainers / Losers as of 1:00 PM\" data-tweet=\"$ASA $FAC $DHCP - Financials - Top 5 Gainers / Losers as of 1:00 PM https://seekingalpha.com/news/3233708-financials-top-5-gainers-losers-of-1-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3233708-financials-top-5-gainers-losers-of-1-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233711\" data-ts=\"1483639202\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DVAX\" target=\"_blank\">DVAX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233711-dynavax-stops-making-heplisav-b-and-axes-38-of-workforce-shares-ease-5\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dynavax stops making HEPLISAV-B and axes 38% of workforce; shares ease 5%</a></h4><ul><li>With the aim of <a href=\"https://seekingalpha.com/pr/16706698-dynavax-restructures-emphasizes-immuno-oncology-program\" target=\"_blank\">extending its cash runway</a> while it focuses its development efforts in immuno-oncology, Dynavax (<a href='https://seekingalpha.com/symbol/DVAX' title='Dynavax Technologies Corporation'>DVAX</a> <font color='red'>-4.5%</font>) suspends manufacturing of hepatitis B vaccine candidate HEPLISAV-B and cuts global headcount by 38%. It will book the majority of the ~$3M restructuring charge this quarter. The company says the changes should reduce cash burn by 40%.</li><li>Going forward, it expects to incur HEPLISAV-B costs of less than $1M per month while it works through the CRL it received from the FDA in November. Operating costs related to its oncology program should be less than $60M per annum.</li><li>The company's lead oncology candidate is <a href=\"http://www.dynavax.com/our-pipeline/cancer-immunotherapy/sd101/\" target=\"_blank\">SD-101</a>, an intratumoral TLR9 agonist, in early/mid-stage development for solid tumors and blood cancers.</li></ul><div class=\"tiny-share-widget\" data-id=\"3233711\" data-linked=\"Dynavax stops making HEPLISAV-B and axes 38% of workforce; shares ease 5%\" data-tweet=\"$DVAX - Dynavax stops making HEPLISAV-B and axes 38% of workforce; shares ease 5% https://seekingalpha.com/news/3233711-dynavax-stops-making-heplisav-b-and-axes-38-of-workforce-shares-ease-5?source=tweet\" data-url=\"https://seekingalpha.com/news/3233711-dynavax-stops-making-heplisav-b-and-axes-38-of-workforce-shares-ease-5\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>44&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233712\" data-ts=\"1483639069\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AGI\" target=\"_blank\">AGI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233712-alamos-gold-wins-forestry-permits-for-kirazli-project\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Alamos Gold wins forestry permits for Kirazli project</a></h4><ul>     <li>Alamos Gold (<a href='https://seekingalpha.com/symbol/AGI' title='Alamos Gold Inc'>AGI</a> <font color='green'>+12.7%</font>) surges on news it <a href=\"https://seekingalpha.com/pr/16705742-alamos-receives-forestry-permits-kirazli-project\" target=\"_blank\">received forestry permits</a> required for the development of its Kirazli gold project from Turkey's government.</li>     <li>AGI, which considers Kirazli its highest return  project and a significant source of free cash flow in the years ahead, says the permits are a significant  breakthrough for the project.</li><li>AGI says feasibility studies to update the economics for both the Kirazli and Agi Dagi projects are nearing  completion, and a preliminary economic assessment on the higher grade Camyurt project also is underway.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3233712\" data-linked=\"Alamos Gold wins forestry permits for Kirazli project\" data-tweet=\"$AGI - Alamos Gold wins forestry permits for Kirazli project https://seekingalpha.com/news/3233712-alamos-gold-wins-forestry-permits-for-kirazli-project?source=tweet\" data-url=\"https://seekingalpha.com/news/3233712-alamos-gold-wins-forestry-permits-for-kirazli-project\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:57 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233709\" data-ts=\"1483638772\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233709-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul> <li><b>Gainers:</b> ETRM <font color='green'>+90%</font>. <a href='https://seekingalpha.com/symbol/PRAN' title='Prana Biotechnology Ltd'>PRAN</a> <font color='green'>+39%</font>. <a href='https://seekingalpha.com/symbol/PIRS' title='Pieris Pharmaceuticals, Inc.'>PIRS</a> <font color='green'>+22%</font>. <a href='https://seekingalpha.com/symbol/CEB' title='CEB Inc.'>CEB</a> <font color='green'>+21%</font>. <a href='https://seekingalpha.com/symbol/CTIC' title='CTI BioPharma Corp.'>CTIC</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/HALO' title='Halozyme Therapeutics, Inc.'>HALO</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/AXU' title='Alexco Resource Corporation'>AXU</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/BCEI' title='Bonanza Creek Energy'>BCEI</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/GORO' title='Gold Resource Corporation'>GORO</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/OTIC' title='Otonomy'>OTIC</a> <font color='green'>+12%</font>.</li> <li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/AEZS' title='AEterna Zentaris, Inc.'>AEZS</a> <font color='red'>-24%</font>. <a href='https://seekingalpha.com/symbol/KSS' title='Kohl&#39;s Corporation'>KSS</a> <font color='red'>-20%</font>. <a href='https://seekingalpha.com/symbol/BIOS' title='BioScrip, Inc.'>BIOS</a> <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/XXII' title='22nd Century Group, Inc.'>XXII</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/CSLT' title='Castlight Health, Inc.'>CSLT</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/M' title='Macy&#39;s Inc.'>M</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/FFHL' title='Fuwei Films &#40;Holdings&#41; Co., Ltd.'>FFHL</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/RECN' title='Resources Connection, Inc.'>RECN</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/PSIX' title='Power Solutions International, Inc.'>OTCPK:PSIX</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/CGG-OLD' title='CGG'>CGG-OLD</a> <font color='red'>-12%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3233709\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$RSLS $ATHE $PIRS - Midday Gainers / Losers https://seekingalpha.com/news/3233709-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3233709-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:52 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233705\" data-ts=\"1483638224\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PRAN\" target=\"_blank\">PRAN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233705-prana-bio-shows-life-shares-up-44\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Prana Bio shows some life; shares up 44%</a></h4><ul><li>Thinly traded Prana Biotechnology (<a href='https://seekingalpha.com/symbol/PRAN' title='Prana Biotechnology Ltd'>PRAN</a> <font color='green'>+44%</font>) continues its up move on an impressive 29x surge in volume. Shares have rallied almost 70% since trading resumed Tuesday.</li><li>No particular news accounts for the action. It recently reported meeting with European regulators to clarify a path to a Phase 3 clinical trial for lead product candidate PBT2. It appears that it will need to conduct additional preclinical testing to assess safety issues before getting clearance to start human studies.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3232377-prana-biotech-quite-start-european-late-stage-study-lead-product-candidate-huntingtons\" target=\"_blank\">Prana Biotech not quite there for start of European late-stage study of lead product candidate in Huntington's</a> (Dec. 23, 2016)</li></ul><div class=\"tiny-share-widget\" data-id=\"3233705\" data-linked=\"Prana Bio shows some life; shares up 44%\" data-tweet=\"$PRAN $ATHE - Prana Bio shows some life; shares up 44% https://seekingalpha.com/news/3233705-prana-bio-shows-life-shares-up-44?source=tweet\" data-url=\"https://seekingalpha.com/news/3233705-prana-bio-shows-life-shares-up-44\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:43 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233695\" data-ts=\"1483635733\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233695-consumer-top-gainers-losers-of-12-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/WILC' title='G. Willi-Food International, Ltd.'>WILC</a> <font color='green'>+7%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/SQBG' title='Sequential Brands Group, Inc.'>SQBG</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/FOSL' title='Fossil, Inc.'>FOSL</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/LZB' title='La-Z-Boy Incorporated'>LZB</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/GIII' title='G-III Apparel Group, LTD.'>GIII</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/OTIV' title='On Track Innovations Ltd'>OTIV</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3233695\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 pm\" data-tweet=\"$WILC $SQBG $FOSL - Consumer - Top Gainers / Losers as of 12:00 pm https://seekingalpha.com/news/3233695-consumer-top-gainers-losers-of-12-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3233695-consumer-top-gainers-losers-of-12-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:02 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233694\" data-ts=\"1483635419\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BKS\" target=\"_blank\">BKS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233694-barnes-nobleminus-7-after-guidance-update\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Barnes &amp; Noble -7% after guidance update</a></h4><ul><li>Barnes &amp; Noble (NYSE:<a href='https://seekingalpha.com/symbol/BKS' title='Barnes & Noble Inc'>BKS</a>) sees FY17 comparable sales falling 6%.</li><li>FY17 retail EBITDA of $225M is anticipated. Nook is expected to sap away $25M in EBITDA.</li><li>Shares of B&amp;N are&nbsp;<font color='red'>down over 7%</font>, news of an Amazon bookstore launch in Manhattan isn't helping to bring in new buyers.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3233667-amazon-plans-manhattan-bookstore\" target=\"_blank\">Amazon plans Manhattan bookstore</a> (Jan. 5)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3233628-holiday-sales-fall-barnes-and-noble\" target=\"_blank\">Holiday sales fall at Barnes &amp; Noble</a> (Jan. 5)</li></ul><div class=\"tiny-share-widget\" data-id=\"3233694\" data-linked=\"Barnes &amp; Noble -7% after guidance update\" data-tweet=\"$BKS - Barnes &amp; Noble -7% after guidance update https://seekingalpha.com/news/3233694-barnes-nobleminus-7-after-guidance-update?source=tweet\" data-url=\"https://seekingalpha.com/news/3233694-barnes-nobleminus-7-after-guidance-update\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:56 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233689\" data-ts=\"1483634899\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HGEN\" target=\"_blank\">HGEN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233689-fda-in-line-kalobios-pharmas-plan-for-abbreviated-marketing-application-for-benznidazole\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA in line with KaloBios Pharma&#39;s plan for abbreviated marketing application for benznidazole; shares ahead 13%</a></h4><ul><li>Thinly traded nano cap KaloBios Pharmaceuticals (KBIO <font color='green'>+13.4%</font>) perks up on modest volume in response to its <a href=\"https://seekingalpha.com/pr/16706583-kalobios-announces-positive-guidance-fda-benznidazole\" target=\"_blank\">announcement </a>that the FDA is on board with the key elements in its development plan for Chagas disease drug benznidazole, including its intent to use the abbreviated 505(b)(2) regulatory pathway which allows some of the supporting data to be derived from studies performed by others.</li><li>In other news, the company will present a business update to investors on Tuesday, January 10 at 11:00 am ET at the Biotech Showcase in San Francisco.</li></ul><div class=\"tiny-share-widget\" data-id=\"3233689\" data-linked=\"FDA in line with KaloBios Pharma&#39;s plan for abbreviated marketing application for benznidazole; shares ahead 13%\" data-tweet=\"$HGEN - FDA in line with KaloBios Pharma&#39;s plan for abbreviated marketing application for benznidazole; shares ahead 13% https://seekingalpha.com/news/3233689-fda-in-line-kalobios-pharmas-plan-for-abbreviated-marketing-application-for-benznidazole?source=tweet\" data-url=\"https://seekingalpha.com/news/3233689-fda-in-line-kalobios-pharmas-plan-for-abbreviated-marketing-application-for-benznidazole\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:48 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233692\" data-ts=\"1483634791\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IPG\" target=\"_blank\">IPG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233692-interpublic-groupminus-2_4-morgan-stanley-goes-neutral\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Interpublic Group -2.4% as Morgan Stanley goes Neutral</a></h4><ul>   <li>Ad giant Interpublic Group (NYSE:<a href='https://seekingalpha.com/symbol/IPG' title='Interpublic Group of Companies Inc.'>IPG</a>) is <font color='red'>2.4% lower</font> after a Morgan Stanley downgrade to Equalweight.</li>    <li>\"We <a href=\"http://www.streetinsider.com/Analyst+Comments/Morgan+Stanley+Downgrades+Interpublic+Group+%28IPG%29+to+Equalweight%2C+Raises+PT+To+%2486.00/12395495.html\" target=\"_blank\">no longer have a more bullish outlook</a> than consensus for IPG, and expect organic growth to moderate in '17,\" says analyst Ben Swinburne. \"Both IPG/<a href='https://seekingalpha.com/symbol/OMC' title='Omnicom Group Inc.'>OMC</a> face a stronger dollar (40% int'l revs) and DOJ investigation overhangs. Finally, agencies' more defensive secular position versus traditional media appears priced in.\"</li>    <li>Swinburne updated the firm's price target on IPG to $26; shares are trading at $23.07 today after closing at $23.63 yesterday. The stock is <font color='red'>down 0.8%</font> over the past 12 months.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3233692\" data-linked=\"Interpublic Group -2.4% as Morgan Stanley goes Neutral\" data-tweet=\"$IPG $IPG $OMC - Interpublic Group -2.4% as Morgan Stanley goes Neutral https://seekingalpha.com/news/3233692-interpublic-groupminus-2_4-morgan-stanley-goes-neutral?source=tweet\" data-url=\"https://seekingalpha.com/news/3233692-interpublic-groupminus-2_4-morgan-stanley-goes-neutral\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:46 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233691\" data-ts=\"1483634614\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CGG-OLD\" target=\"_blank\">CGG-OLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233691-cgg-eyes-financial-restructuring-sees-after-sales-volume-below-expectations\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CGG eyes financial restructuring, sees after-sales volume below expectations</a></h4><ul>     <li>French geophysical services company CGG (<a href='https://seekingalpha.com/symbol/CGG-OLD' title='CGG'>CGG-OLD</a> <font color='red'>-12.6%</font>) says it is looking to start discussions with stakeholders to achieve a <a href=\"http://www.rigzone.com/news/oil_gas/a/147996/CGG_Looks_to_Achieve_Financial_Restructuring\" target=\"_blank\">financial restructuring</a>.</li><li>CGG says it would seek a level of indebtedness and cost of debt that is  substantially reduced and sustainably adapted to its revenues.</li><li>CGG says the market remains difficult, as multi-client sales are  estimated at ~$135M in Q4 2016, with a  level of prefunding in line with its target - a pre-funding rate above 80% on  an annual basis - but an after-sales volume below expectations.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3233691\" data-linked=\"CGG eyes financial restructuring, sees after-sales volume below expectations\" data-tweet=\"$CGG-OLD - CGG eyes financial restructuring, sees after-sales volume below expectations https://seekingalpha.com/news/3233691-cgg-eyes-financial-restructuring-sees-after-sales-volume-below-expectations?source=tweet\" data-url=\"https://seekingalpha.com/news/3233691-cgg-eyes-financial-restructuring-sees-after-sales-volume-below-expectations\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:43 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233690\" data-ts=\"1483634583\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BAC\" target=\"_blank\">BAC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233690-financials-sink-alongside-rates-and-retail\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials sink alongside rates and retail</a></h4><ul><li>The S&amp;P 500 is<font color='red'> lower by just 0.3%</font>, but the financial sector (<a href='https://seekingalpha.com/symbol/XLF' title='Financial Select Sector SPDR ETF'>XLF</a> <font color='red'>-1.9%</font>) is taking a sizable breather from its big post-election run.</li><li>Those buying on hopes for the long-awaited sustained rise in interest rates might be pausing as the 10-year yield sinks seven basis points to 2.37%. Two weeks ago, it was at 2.60%.</li><li>Bond bears have at least a couple of excuses to lighten up today. One might be <a href=\"https://seekingalpha.com/news/3233639-treasury-yields-lower-mixed-data\" target=\"_blank\">softer-than-hoped</a> jobs numbers from ADP. Or maybe economy bulls are mulling&nbsp;<a href=\"https://seekingalpha.com/news/3233670-department-stores-ground-zero-retail-shellacking\" target=\"_blank\">the carnage</a> in retail (<a href='https://seekingalpha.com/symbol/XRT' title='SPDR S&P Retail ETF'>XRT</a> <font color='red'>-3.2%</font>) - unless you happen to be Amazon (<font color='green'>+2.3%</font>) - following guidance, job, and store cuts at Macy's, and another 150 closings at Sears, as well as weak numbers from players like Kohl's.</li><li>Bank of America (<a href='https://seekingalpha.com/symbol/BAC' title='Bank of America Corporation'>BAC</a> <font color='red'>-2.6%</font>), Citigroup (<a href='https://seekingalpha.com/symbol/C' title='Citigroup Inc.'>C</a> <font color='red'>-2.3%</font>), Wells Fargo (<a href='https://seekingalpha.com/symbol/WFC' title='Wells Fargo & Co.'>WFC</a> <font color='red'>-2.8%</font>), JPMorgan (<a href='https://seekingalpha.com/symbol/JPM' title='JPMorgan Chase & Co.'>JPM</a> <font color='red'>-1.9%</font>), Morgan Stanley (<a href='https://seekingalpha.com/symbol/MS' title='Morgan Stanley'>MS</a> <font color='red'>-3.1%</font>), Regions Financial (<a href='https://seekingalpha.com/symbol/RF' title='Regions Financial Corporation'>RF</a> <font color='red'>-2.6%</font>), U.S. Bancorp (<a href='https://seekingalpha.com/symbol/USB' title='U.S. Bancorp'>USB</a> <font color='red'>-1.9%</font>), KeyCorp (<a href='https://seekingalpha.com/symbol/KEY' title='KeyCorp'>KEY</a> <font color='red'>-1.7%</font>), Fifth Third (<a href='https://seekingalpha.com/symbol/FITB' title='Fifth Third Bancorp'>FITB</a> <font color='red'>-2.9%</font>), Schwab (<a href='https://seekingalpha.com/symbol/SCHW' title='The Charles Schwab Corporation'>SCHW</a> <font color='red'>-1.5%</font>), MetLife (<a href='https://seekingalpha.com/symbol/MET' title='MetLife, Inc.'>MET</a> <font color='red'>-2.4%</font>), AIG (<a href='https://seekingalpha.com/symbol/AIG' title='American International Group Inc'>AIG</a> <font color='red'>-1.4%</font>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3233690\" data-linked=\"Financials sink alongside rates and retail\" data-tweet=\"$BAC $XLF $XRT - Financials sink alongside rates and retail https://seekingalpha.com/news/3233690-financials-sink-alongside-rates-and-retail?source=tweet\" data-url=\"https://seekingalpha.com/news/3233690-financials-sink-alongside-rates-and-retail\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:43 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>61&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233684\" data-ts=\"1483634250\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IONS\" target=\"_blank\">IONS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233684-ionis-candidate-for-muscle-wasting-disease-flunks-mid-stage-study-shares-off-6\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ionis&#39; candidate for muscle wasting disease flunks mid-stage study; shares off 6%</a></h4><ul><li>Despite the positive points emphasized in today's pipleline presentation for investors, Ionis Pharmaceuticals (<a href='https://seekingalpha.com/symbol/IONS' title='Ionis Pharmaceuticals, Inc.'>IONS</a> <font color='red'>-5.9%</font>) slumps on average volume. The culprit is a failed mid-stage study assessing IONIS-DMPK-2.5rx for the treatment of a rare genetic muscle wasting disorder called myotonic dystrophy type 1 (DM1) caused by mutations in a gene called <a href=\"https://ghr.nlm.nih.gov/gene/DMPK\" target=\"_blank\">DMPK</a>. The antisense drug is the company's first candidate designed to address a muscle target.</li><li>The small trial assessed five doses of IONIS-DMPK-2.5rx administered for six weeks. Encouraging trends were observed in certain biomarkers and the drug appeared to be safe and well-tolerated, but the desired potency in muscle was not there.</li><li>Ionis and alliance partner Biogen (<a href='https://seekingalpha.com/symbol/BIIB' title='Biogen Inc.'>BIIB</a> <font color='red'>-0.1%</font>) are working on new LICA (Ligand-Conjugated Antisense) muscle-targeting chemistries in an effort to beef up the potency.</li><li><a href=\"http://ir.ionispharma.com/phoenix.zhtml?c=222170&amp;p=irol-EventDetails&amp;EventId=5245196\" target=\"_blank\">Download presentation here</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3233684\" data-linked=\"Ionis&#39; candidate for muscle wasting disease flunks mid-stage study; shares off 6%\" data-tweet=\"$IONS $IONS $BIIB - Ionis&#39; candidate for muscle wasting disease flunks mid-stage study; shares off 6% https://seekingalpha.com/news/3233684-ionis-candidate-for-muscle-wasting-disease-flunks-mid-stage-study-shares-off-6?source=tweet\" data-url=\"https://seekingalpha.com/news/3233684-ionis-candidate-for-muscle-wasting-disease-flunks-mid-stage-study-shares-off-6\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:37 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233687\" data-ts=\"1483633833\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EMMS\" target=\"_blank\">EMMS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233687-emmisminus-7-revenues-slip-again\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Emmis -7% as revenues slip again</a></h4><ul>   <li>Emmis Communications (NASDAQ:<a href='https://seekingalpha.com/symbol/EMMS' title='Emmis Communications Corporation'>EMMS</a>) has <font color='red'>fallen off 7%</font> after posting another disappointment in <a href=\"https://seekingalpha.com/news/3233569-emmis-communications-reports-fq3-results\" target=\"_blank\">Q3 earnings</a> that saw revenues drop more than 5%.</li>    <li>Publishing revenues fell 18%; pro forma for the company's sale of Texas Monthly, publishing net revenues still declined 6%, and radio revenue fell fractionally overall.</li>    <li>\"Emmis Radio is not accustomed to underperforming its markets,\" says Chairman/CEO Jeff Smulyan. \"I was disappointed in our performance, but remain hopeful that recent ratings gains in Los Angeles and Austin, coupled with continued stellar performance in St. Louis, will lead to better performance in fiscal 2018.\"</li>     <li><a href=\"https://seekingalpha.com/pr/16705709-emmis-announces-third-quarter-earnings\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3233687\" data-linked=\"Emmis -7% as revenues slip again\" data-tweet=\"$EMMS - Emmis -7% as revenues slip again https://seekingalpha.com/news/3233687-emmisminus-7-revenues-slip-again?source=tweet\" data-url=\"https://seekingalpha.com/news/3233687-emmisminus-7-revenues-slip-again\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:30 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233680\" data-ts=\"1483632272\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WMC\" target=\"_blank\">WMC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233680-western-asset-mortgage-ag-mortgage-lose-sell-side-friend\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Western Asset Mortgage, AG Mortgage lose sell-side friend</a></h4><ul><li>Outliers to the downside in the mortgage REIT sector this morning are Western Asset Mortgage (<a href='https://seekingalpha.com/symbol/WMC' title='Western Asset Mortgage Capital Corporation'>WMC</a> <font color='red'>-2.2%</font>) and AG Mortgage (<a href='https://seekingalpha.com/symbol/MITT' title='AG Mortgage Investment Trust, Inc.'>MITT</a> <font color='red'>-1.9%</font>) after Wunderlich's Merrill Ross downgrades each to Hold from Buy.</li><li>Western Asset is<font color='red'> lower by 3.5%</font>&nbsp;Y/Y and currently sells for a 10% discount to Sept. 30 book value.</li><li>AG is&nbsp;<font color='green'>up 31%</font>&nbsp;Y/Y and currently sells for a 6% discount to book. It's&nbsp;<font color='green'>up about 10%</font>&nbsp;since Ross upgraded to a Buy the day before the election.</li></ul><div class=\"tiny-share-widget\" data-id=\"3233680\" data-linked=\"Western Asset Mortgage, AG Mortgage lose sell-side friend\" data-tweet=\"$WMC $WMC $MITT - Western Asset Mortgage, AG Mortgage lose sell-side friend https://seekingalpha.com/news/3233680-western-asset-mortgage-ag-mortgage-lose-sell-side-friend?source=tweet\" data-url=\"https://seekingalpha.com/news/3233680-western-asset-mortgage-ag-mortgage-lose-sell-side-friend\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:04 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233668\" data-ts=\"1483632110\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233668-healthcare-top-5-gainers-losers-of-11-00\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 am</a></h4><ul>     <li><b>Gainers:</b> ETRM <font color='green'>+95%</font>. <a href='https://seekingalpha.com/symbol/PRAN' title='Prana Biotechnology Ltd'>PRAN</a> <font color='green'>+36%</font>. <a href='https://seekingalpha.com/symbol/PIRS' title='Pieris Pharmaceuticals, Inc.'>PIRS</a> <font color='green'>+29%</font>. <a href='https://seekingalpha.com/symbol/CTIC' title='CTI BioPharma Corp.'>CTIC</a> <font color='green'>+20%</font>. <a href='https://seekingalpha.com/symbol/HALO' title='Halozyme Therapeutics, Inc.'>HALO</a> <font color='green'>+13%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/AEZS' title='AEterna Zentaris, Inc.'>AEZS</a> <font color='red'>-27%</font>. <a href='https://seekingalpha.com/symbol/XXII' title='22nd Century Group, Inc.'>XXII</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/BIOS' title='BioScrip, Inc.'>BIOS</a> <font color='red'>-10%</font>. EBIO <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/OREX' title='Orexigen Therapeutics, Inc.'>OREX</a> <font color='red'>-8%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3233668\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 am\" data-tweet=\"$RSLS $ATHE $PIRS - Healthcare - Top 5 Gainers / Losers as of 11:00 am https://seekingalpha.com/news/3233668-healthcare-top-5-gainers-losers-of-11-00?source=tweet\" data-url=\"https://seekingalpha.com/news/3233668-healthcare-top-5-gainers-losers-of-11-00\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:01 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233679\" data-ts=\"1483632062\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233679-crude-inventory-falls-sharply\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Crude inventory falls sharply</a></h4><ul><li><a href=\"http://ir.eia.gov/wpsr/wpsrsummary.pdf\" target=\"_blank\">EIA Petroleum Inventories</a>:</li><li>Crude <strong>-7.1</strong><strong>M</strong> barrels vs. -2.2M consensus, +0.6M last week.</li><li>Gasoline <strong>+8.3</strong><strong>M</strong> barrels vs. +1.8M consensus, -1.6M last week.</li><li>Distillates <strong>+10</strong><strong>M</strong> barrels vs. +1.1M consensus, -1.9M last week.</li><li>Futures&nbsp;<font color='green'>+0.50%</font>&nbsp;to $53.52.</li><li>ETFs:<a href='https://seekingalpha.com/symbol/USO' title='The United States Oil ETF, LP'>USO</a>,                     <a href='https://seekingalpha.com/symbol/OIL' title='iPath S&P Crude Oil Total Return Index ETN'>OIL</a>, <a href='https://seekingalpha.com/symbol/UCO' title='ProShares Ultra Bloomberg Crude Oil ETF'>UCO</a>, <a href='https://seekingalpha.com/symbol/SCO' title='ProShares UltraShort Bloomberg Crude Oil ETF'>SCO</a>, <a href='https://seekingalpha.com/symbol/BNO' title='The United States Brent Oil ETF, LP'>BNO</a>, <a href='https://seekingalpha.com/symbol/DTO' title='DB Crude Oil Double Short ETN'>DTO</a>,  <a href='https://seekingalpha.com/symbol/DBO' title='PowerShares DB Oil ETF'>DBO</a>,           <a href='https://seekingalpha.com/symbol/UWT' title='VelocityShares 3X Long Crude ETN'>UWT</a>,          <a href='https://seekingalpha.com/symbol/USL' title='The United States 12 Month Oil ETF, LP'>USL</a>, <a href='https://seekingalpha.com/symbol/DWT' title='VelocityShares 3x Inverse Crude Oil ETN'>DWT</a>, <a href='https://seekingalpha.com/symbol/DNO' title='The United States Short Oil ETF, LP'>DNO</a>,  <a href='https://seekingalpha.com/symbol/SZO' title='DB Crude Oil Short ETN'>SZO</a>,  <a href='https://seekingalpha.com/symbol/OLO' title='DB Crude Oil Long ETN'>OLO</a>,          <a href='https://seekingalpha.com/symbol/OLEM' title='iPath Pure Beta Crude Oil ETN'>OLEM</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3233679\" data-linked=\"Crude inventory falls sharply\" data-tweet=\"$USO $OIL $UCO - Crude inventory falls sharply https://seekingalpha.com/news/3233679-crude-inventory-falls-sharply?source=tweet\" data-url=\"https://seekingalpha.com/news/3233679-crude-inventory-falls-sharply\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:01 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>23&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233676\" data-ts=\"1483631111\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DISCA\" target=\"_blank\">DISCA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233676-discovery-communicationsminus-1_9-barclays-cuts-to-sell\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Discovery Communications -1.9% as Barclays cuts to Sell</a></h4><ul>   <li>Discovery Communications (NASDAQ:<a href='https://seekingalpha.com/symbol/DISCA' title='Discovery Inc A'>DISCA</a>) is <font color='red'>off 1.9%</font> after Barclays cut its rating to Underweight and trimmed its price target.</li>    <li>The stock <a href=\"http://www.streetinsider.com/Analyst+Comments/Barclays+Downgrades+Discovery+Communications+%28DISCA%29+To+Underweight%2C+Calls+Valuation+Rich/12395146.html\" target=\"_blank\">looks \"rich or cheap\"</a> depending on which metric you're looking at, writes Kannan Venkateshwar.</li>    <li>\"While the stock appears cheap on cash flow and P/E, these metrics for DISCA have been more volatile than for others in the space. While DISCA revenues are up ~44% since 2012 in part due to M&amp;A, profit before taxes is up only 7%.\"</li>    <li>The company's free cash flow has turned up only recently after a flat three years, he adds. \"On EV/EBITDA, which is our preferred metric, the company is one of the most expensive, trading just ~0.5x lower than Disney.\"</li>    <li>He trimmed his price target on shares to $25 from $28, implying another 10% downside ahead.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3233676\" data-linked=\"Discovery Communications -1.9% as Barclays cuts to Sell\" data-tweet=\"$DISCA $DISCB $DISCK - Discovery Communications -1.9% as Barclays cuts to Sell https://seekingalpha.com/news/3233676-discovery-communicationsminus-1_9-barclays-cuts-to-sell?source=tweet\" data-url=\"https://seekingalpha.com/news/3233676-discovery-communicationsminus-1_9-barclays-cuts-to-sell\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:45 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233673\" data-ts=\"1483631059\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PIRS\" target=\"_blank\">PIRS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233673-pieris-pharma-teams-up-servier-in-immuno-oncology-shares-up-31\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pieris Pharma teams up Servier in immuno-oncology; shares up 31%</a></h4><ul><li>Thinly traded nano cap Pieris Pharmaceuticals (<a href='https://seekingalpha.com/symbol/PIRS' title='Pieris Pharmaceuticals, Inc.'>PIRS</a> <font color='green'>+30.6%</font>) heads north on a healthy 14x surge in volume in response to its <a href=\"https://seekingalpha.com/pr/16705793-pieris-pharmaceuticals-servier-forge-strategic-immuno-oncology-co-development-alliance\" target=\"_blank\">announcement</a> of a co-development alliance with Servier in immuno-oncology. Specifically, the companies will jointly pursue several bispecific therapeutic programs including Pieris' dual checkpoint inhibitor PRS-332 as well as four additional programs (may be expanded to eight). Pieris has the option to co-develop and retain U.S. rights for four programs.</li><li>Under the terms of the agreement, Pieris will receive &euro;30M upfront, up to &euro;324M in milestones related to PRS-332, up to &euro;193M in milestones related to each of the other programs and up to double-digit royalties.</li></ul><div class=\"tiny-share-widget\" data-id=\"3233673\" data-linked=\"Pieris Pharma teams up Servier in immuno-oncology; shares up 31%\" data-tweet=\"$PIRS - Pieris Pharma teams up Servier in immuno-oncology; shares up 31% https://seekingalpha.com/news/3233673-pieris-pharma-teams-up-servier-in-immuno-oncology-shares-up-31?source=tweet\" data-url=\"https://seekingalpha.com/news/3233673-pieris-pharma-teams-up-servier-in-immuno-oncology-shares-up-31\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:44 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233672\" data-ts=\"1483630251\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233672-natural-gas-futures-fall-post-inventory-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Natural gas futures fall post inventory data</a></h4><ul>     <li><a href=\"http://ir.eia.gov/ngs/ngs.html\" target=\"_blank\">EIA Natural Gas Inventory</a>: <strong>-49</strong><strong> Bcf</strong> vs. -82 Bcf consensus -237 Bcf last week.</li><li>Futures <font color='red'>-1.44%</font>&nbsp;to $3.220.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/UNG' title='The United States Natural Gas ETF, LP'>UNG</a>, <a href='https://seekingalpha.com/symbol/DGAZ' title='VelocityShares 3x Inverse Natural Gas ETN'>DGAZ</a>, <a href='https://seekingalpha.com/symbol/UGAZ' title='VelocityShares 3x Long Natural Gas ETN'>UGAZ</a>, <a href='https://seekingalpha.com/symbol/BOIL' title='ProShares Ultra Bloomberg Natural Gas ETF'>BOIL</a>, <a href='https://seekingalpha.com/symbol/GAZ' title='iPath DJ-UBS Natural Gas Total Return Sub-Index ETN'>GAZ</a>, <a href='https://seekingalpha.com/symbol/KOLD' title='ProShares UltraShort Bloomberg Natural Gas ETF'>KOLD</a>, <a href='https://seekingalpha.com/symbol/UNL' title='The United States 12 Month Natural Gas ETF, LP'>UNL</a>, <a href='https://seekingalpha.com/symbol/DCNG' title='iPath Pure Beta Seasonal Natural Gas ETN'>DCNG</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3233672\" data-linked=\"Natural gas futures fall post inventory data\" data-tweet=\"$UNG $DGAZ $UGAZ - Natural gas futures fall post inventory data https://seekingalpha.com/news/3233672-natural-gas-futures-fall-post-inventory-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3233672-natural-gas-futures-fall-post-inventory-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>30&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233671\" data-ts=\"1483630126\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RJF\" target=\"_blank\">RJF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233671-nomura-reshuffles-brokerage-ratings-after-post-election-rally\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nomura reshuffles brokerage ratings after post-election rally</a></h4><ul><li>The post-election rally is notable for its \"indiscriminate\" buying of financial sector names, particularly large-caps, says Nomura's Steven Chubak. That's fine, he says, as it leaves \"a very compelling\" buying opportunity in a number of small- and mid-cap names which are set to be big winners under a Trump administration.</li><li>He upgrades Raymond James Financial (<a href='https://seekingalpha.com/symbol/RJF' title='Raymond James Financial Inc.'>RJF</a> <font color='green'>+1.6%</font>) and TD Ameritrade (<a href='https://seekingalpha.com/symbol/AMTD' title='TD Ameritrade Holding Corporation'>AMTD</a> <font color='green'>+1.4%</font>) to Buy, and even suggests a pair trade of long Stifel (NYSE:<a href='https://seekingalpha.com/symbol/SF' title='Stifel Financial Corporation'>SF</a>) and Raymond James vs. a short in LPL Financial (<a href='https://seekingalpha.com/symbol/LPLA' title='LPL Financial Holdings Inc.'>LPLA</a> <font color='red'>-0.4%</font>).</li><li>Cut are made to Lazard (<a href='https://seekingalpha.com/symbol/LAZ' title='Lazard Ltd.'>LAZ</a> <font color='red'>-1.1%</font>) and Greenhill (<a href='https://seekingalpha.com/symbol/GHL' title='Greenhill & Co., Inc.'>GHL</a> <font color='red'>-3.6%</font>) as the Trump rally overlooks the headwinds of protectionism and financing costs.</li><li>Turning to big-caps, Chubak is growing more cautious on M&amp;A as he sees deal risks rising under Trump. He suggests a buy of Bank of America (<a href='https://seekingalpha.com/symbol/BAC' title='Bank of America Corporation'>BAC</a> <font color='red'>-0.8%</font>) vs. a sale of Goldman Sachs (<a href='https://seekingalpha.com/symbol/GS' title='Goldman Sachs Group Inc.'>GS</a> <font color='red'>-0.2%</font>).</li><li>Source: Bloomberg</li></ul><div class=\"tiny-share-widget\" data-id=\"3233671\" data-linked=\"Nomura reshuffles brokerage ratings after post-election rally\" data-tweet=\"$RJF $RJF $AMTD - Nomura reshuffles brokerage ratings after post-election rally https://seekingalpha.com/news/3233671-nomura-reshuffles-brokerage-ratings-after-post-election-rally?source=tweet\" data-url=\"https://seekingalpha.com/news/3233671-nomura-reshuffles-brokerage-ratings-after-post-election-rally\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:28 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233666\" data-ts=\"1483629814\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CTIC\" target=\"_blank\">CTIC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233666-fda-lifts-clinical-hold-on-cti-bios-pacritinib-shares-up-26\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA lifts clinical hold on CTI Bio&#39;s pacritinib; shares up 26%</a></h4><ul><li>Thinly traded micro cap CTI BioPharma (<a href='https://seekingalpha.com/symbol/CTIC' title='CTI BioPharma Corp.'>CTIC</a> <font color='green'>+26.2%</font>) rallies on almost an 8x surge in volume in response to its <a href=\"https://seekingalpha.com/pr/16705648-cti-biopharma-announces-removal-full-clinical-hold-pacritinib\" target=\"_blank\">announcement</a> that the FDA has removed the full clinical hold on myelofibrosis candidate pacritinib. The agency suspended clinical development in February over safety concerns, which the company addressed with final results from two studies, PERSIST-1 and PERSIST-2.</li><li>A new trial, PAC203, should commence next quarter.</li><li><a href=\"http://www.ctibiopharma.com/pipeline/pacritinib/\" target=\"_blank\">Pacritinib</a>, an oral tyrosine kinase inhibitor, is under development for the potential treatment of certain blood-related cancers.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3094906-fda-shuts-cti-bios-pacritinib-clinical-trials-shares-46-percent-premarket\" target=\"_blank\">FDA shuts down CTI Bio's pacritinib clinical trials; shares down 46% premarket</a> (Feb. 9, 2016)</li></ul><div class=\"tiny-share-widget\" data-id=\"3233666\" data-linked=\"FDA lifts clinical hold on CTI Bio&#39;s pacritinib; shares up 26%\" data-tweet=\"$CTIC - FDA lifts clinical hold on CTI Bio&#39;s pacritinib; shares up 26% https://seekingalpha.com/news/3233666-fda-lifts-clinical-hold-on-cti-bios-pacritinib-shares-up-26?source=tweet\" data-url=\"https://seekingalpha.com/news/3233666-fda-lifts-clinical-hold-on-cti-bios-pacritinib-shares-up-26\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:23 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233670\" data-ts=\"1483629772\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KSS\" target=\"_blank\">KSS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233670-department-stores-ground-zero-for-retail-shellacking\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Department stores ground zero for retail shellacking</a></h4><ul> <li>A barrage of disappointing sales reports and guidance cuts from retailers is roiling the broad sector.</li> <li>The department store sector is ground zero for the damage. Kohl's (<a href='https://seekingalpha.com/symbol/KSS' title='Kohl&#39;s Corporation'>KSS</a> <font color='red'>-18.1%</font>), Macy's (<a href='https://seekingalpha.com/symbol/M' title='Macy&#39;s Inc.'>M</a> <font color='red'>-14.5%</font>), Nordstrom (<a href='https://seekingalpha.com/symbol/JWN' title='Nordstrom Inc.'>JWN</a> <font color='red'>-8.9%</font>), Dillard's (<a href='https://seekingalpha.com/symbol/DDS' title='Dillard&#39;s Inc.'>DDS</a> <font color='red'>-9.3%</font>) and J.C. Penney (<a href='https://seekingalpha.com/symbol/JCP' title='J.C. Penney Company Inc.'>JCP</a> <font color='red'>-7.3%</font>) are all down sharply.</li> <li>Chains also bleeding include Cato (<a href='https://seekingalpha.com/symbol/CATO' title='The Cato Corporation'>CATO</a> <font color='red'>-9.6%</font>), Tailored Brands (<a href='https://seekingalpha.com/symbol/TLRD' title='Tailored Brands, Inc'>TLRD</a> <font color='red'>-6.3%</font>), L Brands (<a href='https://seekingalpha.com/symbol/LB' title='L Brands, Inc.'>LB</a> <font color='red'>-7.5%</font>), Ascena Retail (<a href='https://seekingalpha.com/symbol/ASNA' title='Ascena Retail Group Inc'>ASNA</a> <font color='red'>-5.7%</font>), Francesca's (<a href='https://seekingalpha.com/symbol/FRAN' title='Francesca&#39;s Holdings Corp.'>FRAN</a> <font color='red'>-6.5%</font>), Stein Mart (<a href='https://seekingalpha.com/symbol/SMRT' title='Stein Mart, Inc.'>SMRT</a> <font color='red'>-4.7%</font>), Stage Stores (<a href='https://seekingalpha.com/symbol/SSI' title='Stage Stores, Inc.'>SSI</a> <font color='red'>-5.8%</font>), Urban Outiffters (<a href='https://seekingalpha.com/symbol/URBN' title='Urban Outfitters, Inc.'>URBN</a> <font color='red'>-4.4%</font>), DSW (<a href='https://seekingalpha.com/symbol/DSW' title='DSW Inc.'>DSW</a> <font color='red'>-3.8%</font>), Express (<a href='https://seekingalpha.com/symbol/EXPR' title='Express, Inc.'>EXPR</a> <font color='red'>-3.8%</font>), Citi Trends (<a href='https://seekingalpha.com/symbol/CTRN' title='Citi Trends, Inc.'>CTRN</a> <font color='red'>-4.3%</font>).</li> <li>Apparel makers Fossil (<a href='https://seekingalpha.com/symbol/FOSL' title='Fossil, Inc.'>FOSL</a> <font color='red'>-6.5%</font>), G-III Apparel (<a href='https://seekingalpha.com/symbol/GIII' title='G-III Apparel Group, LTD.'>GIII</a> <font color='red'>-6.6%</font>), Sequential Brands Group (<a href='https://seekingalpha.com/symbol/SQBG' title='Sequential Brands Group, Inc.'>SQBG</a> <font color='red'>-5.5%</font>), Vera Bradley (<a href='https://seekingalpha.com/symbol/VRA' title='Vera Bradley'>VRA</a> <font color='red'>-4.2%</font>) and Coach (COH <font color='red'>-2.5%</font>) are also getting punished.</li> <li>If there's one warning to encapsulate the retail weakness it came from L Brands which cited an <a href=\"https://seekingalpha.com/news/3233598-l-brands-updates-sales-margins\" target=\"_blank\">alarming drop</a> in merchandise margins. It's hard to believe that Amazon (NASDAQ:<a href='https://seekingalpha.com/symbol/AMZN' title='Amazon.com, Inc.'>AMZN</a>) didn't have something to do with that development. By the way, Amazon is&nbsp;<font color='green'>up 2.06%</font>&nbsp;on the day.</li></ul><div class=\"tiny-share-widget\" data-id=\"3233670\" data-linked=\"Department stores ground zero for retail shellacking\" data-tweet=\"$KSS $KSS $M - Department stores ground zero for retail shellacking https://seekingalpha.com/news/3233670-department-stores-ground-zero-for-retail-shellacking?source=tweet\" data-url=\"https://seekingalpha.com/news/3233670-department-stores-ground-zero-for-retail-shellacking\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:22 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>63&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233665\" data-ts=\"1483629266\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SIRI\" target=\"_blank\">SIRI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233665-sirius-xmplus-1_6-2016-subscribers-beat-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sirius XM +1.6% as 2016 subscribers beat guidance</a></h4><ul>   <li>Sirius XM (NASDAQ:<a href='https://seekingalpha.com/symbol/SIRI' title='Sirius XM Holdings Inc.'>SIRI</a>) is <font color='green'>up 1.6%</font> and just a nickel off its 52-week high after it noted that with 2016 in the books, it <a href=\"https://seekingalpha.com/pr/16705942-siriusxm-exceeds-2016-subscriber-guidance-issues-2017-subscriber-financial-guidance\" target=\"_blank\">exceeded its subscriber guidance</a> and expects to meet or exceed guidance on financials.</li>    <li>The company ended the year with more than 31.3M subs after a net gain of more than 1.7M. That surpassed the company's forecast for 1.7M net adds.</li>    <li>Among self-pay subscribers, net adds were 1.66M, exceeding company guidance for 1.6M and bringing that total to about 26M.</li>    <li>Looking ahead to 2017, the company is guiding to self-pay net subscriber adds of about 1.3M. It's also guiding to revenue of $5.3B (vs. consensus for $5.34B); EBITDA of about $2.025B (vs. consensus for $2.033B); and free cash flow of about $1.5B.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3233665\" data-linked=\"Sirius XM +1.6% as 2016 subscribers beat guidance\" data-tweet=\"$SIRI - Sirius XM +1.6% as 2016 subscribers beat guidance https://seekingalpha.com/news/3233665-sirius-xmplus-1_6-2016-subscribers-beat-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3233665-sirius-xmplus-1_6-2016-subscribers-beat-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:14 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233664\" data-ts=\"1483629015\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SHLDQ\" target=\"_blank\">SHLDQ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233664-sears-closes-150-stores-and-pulls-liquidity-levers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sears closes 150 stores and pulls liquidity levers</a></h4><ul> <li>Sears Holdings (SHLD <font color='green'>+4%</font>) says it will <a href=\"https://seekingalpha.com/pr/16706368-sears-holdings-announces-steps-enhance-liquidity-stabilize-operating-performance\" target=\"_blank\">close</a> 150 more stores (109 Kmart, 41 Sears) that aren't profitable. The stores generated an EBITDA loss of about $60M over the last 12 months.</li> <li>The company also updates that it sees generating about $1B in liquidity through a series of financing moves.</li> <li>\"We are taking strong, decisive actions today to stabilize the company and improve our financial flexibility in what remains a challenging retail environment,\" said Edward S. Lampert, Chairman &amp; CEO of Sears Holding,\" says Eddie Lampert.</li> <li>Previously: <a href=\"https://seekingalpha.com/news/3233603-sears-unloads-craftsman-stanley-black-and-decker\" target=\"_blank\">Sears unloads Craftsman to Stanley Black &amp; Decker</a> (Jan. 5)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3233664\" data-linked=\"Sears closes 150 stores and pulls liquidity levers\" data-tweet=\"$SHLDQ - Sears closes 150 stores and pulls liquidity levers https://seekingalpha.com/news/3233664-sears-closes-150-stores-and-pulls-liquidity-levers?source=tweet\" data-url=\"https://seekingalpha.com/news/3233664-sears-closes-150-stores-and-pulls-liquidity-levers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:10 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>39&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233660\" data-ts=\"1483628809\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RSLS\" target=\"_blank\">RSLS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233660-enteromedics-says-two-institutions-on-line-vbloc-shares-up-126\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">EnteroMedics says two more institutions on line with vBloc; shares up 126%</a></h4><ul><li>Thinly traded nano cap EnteroMedics (ETRM <font color='green'>+125.8%</font>) rockets north on a healthy 21x surge in volume in response to the <a href=\"https://seekingalpha.com/pr/16705827-enteromedics-announces-vbloc-neurometabolic-therapy-now-available-medstar-health-roper-st\" target=\"_blank\">news </a>that two new medical institutions, MedStar Health in Maryland and Roper St. Francis in South Carolina, have incorporated <a href=\"https://vbloc.com/\" target=\"_blank\">vBloc Therapy</a> and the vBloc Achieve support program into their practices. The additions increase the total vBloc Institute-qualified customer base to 13.</li><li>The obesity treatment involves a pacemaker-like device that delivers&nbsp;vBLOC&nbsp;vagal nerve blocking therapy via electrodes that are surgically implanted subcutaneously in the abdomen. The electrodes are placed in contact with the trunks of the vagus nerves just above the junction between the esophagus and the stomach. The device intermittently blocks vagal nerve signals throughout the patient's waking hours which produces the sensation of fullness.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3203302-two-year-data-show-enteromedics-maestro-device-helps-obese-patients-lose-weight-shares-12\" target=\"_blank\">Two-year data show EnteroMedics' Maestro device helps obese patients lose weight; shares up 12% premarket</a> (Aug. 15, 2016)</li></ul><div class=\"tiny-share-widget\" data-id=\"3233660\" data-linked=\"EnteroMedics says two more institutions on line with vBloc; shares up 126%\" data-tweet=\"$RSLS - EnteroMedics says two more institutions on line with vBloc; shares up 126% https://seekingalpha.com/news/3233660-enteromedics-says-two-institutions-on-line-vbloc-shares-up-126?source=tweet\" data-url=\"https://seekingalpha.com/news/3233660-enteromedics-says-two-institutions-on-line-vbloc-shares-up-126\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:06 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>26&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233656\" data-ts=\"1483628312\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LIVE\" target=\"_blank\">LIVE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233656-live-ventures-names-johnson-new-cfo\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Live Ventures names Johnson new CFO</a></h4><ul>   <li>Live Ventures (<a href='https://seekingalpha.com/symbol/LIVE' title='Live Ventures'>LIVE</a> <font color='red'>-3.2%</font>) has named Virland Johnson its <a href=\"https://seekingalpha.com/pr/16706301-live-ventures-appoints-virland-johnson-chief-financial-officer\" target=\"_blank\">new chief financial officer</a>.</li>    <li>Previously he was senior director of revenue at JDA Software Group, which followed several positions in the Scottsdale, Ariz., area.</li>    <li>He's been working with the company for a couple of months as a consultant.</li>    <li>Shares are <font color='green'>up 45%</font> over the past month but are <font color='red'>down 19.4%</font> in the past five days.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3233656\" data-linked=\"Live Ventures names Johnson new CFO\" data-tweet=\"$LIVE - Live Ventures names Johnson new CFO https://seekingalpha.com/news/3233656-live-ventures-names-johnson-new-cfo?source=tweet\" data-url=\"https://seekingalpha.com/news/3233656-live-ventures-names-johnson-new-cfo\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:58 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233650\" data-ts=\"1483627653\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HALO\" target=\"_blank\">HALO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233650-thestreets-feuerstein-says-halozyme-selective-in-data-read-out-from-mid-stage-pancreatic\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">TheStreet&#39;s Feuerstein says Halozyme selective in data read-out from mid-stage pancreatic cancer study of PEGPH20</a></h4><ul><li>Halozyme (<a href='https://seekingalpha.com/symbol/HALO' title='Halozyme Therapeutics, Inc.'>HALO</a> <font color='green'>+8.6%</font>)&nbsp;has given up a chunk of its Phase 2 data-stoked premarket gain based, in large part, by criticism by TheStreet's <a href=\"https://twitter.com/adamfeuerstein\" target=\"_blank\">Adam Feuerstein</a> who says the company selectively reported results from a subset of patients with high levels of hyaluronan &#40;HA&#41;.</li><li>According to ClinicalTrials.gov, the primary endpoint of the trial, called HALO-202, was progression-free survival at month 12 (another primary objective was to evaluate the incidence of thromboembolic events, which is ongoing). The relative benefit of PEGPH20 in pancreatic cancer patients with high HA was a secondary endpoint.</li><li>The selective reporting of the data does not appear to much of a smoking gun because the Phase 3 study, <a href=\"https://clinicaltrials.gov/ct2/show/NCT02715804?term=NCT02715804&amp;rank=1\" target=\"_blank\">HALO-301</a>, involves metastatic pancreatic cancer patients with high HA levels. The primary endpoints are progression-free survival and overall survival.</li><li><a href=\"https://seekingalpha.com/article/4034493-halozyme-therapeutics-halo-ceo-helen-torley-hosts-investor-day-slides?cache=0.02022080878751198\" target=\"_blank\">Investor presentation</a></li><li>Previously: <a href=\"https://seekingalpha.com/news/3233609-halozymes-lead-product-candidate-shows-positive-effect-mid-stage-pancreatic-cancer-study\" target=\"_blank\">Halozyme's lead product candidate shows positive effect in mid-stage pancreatic cancer study; shares ahead 25% premarket</a> (Jan. 5)</li><li>#JPM17</li></ul><div class=\"tiny-share-widget\" data-id=\"3233650\" data-linked=\"TheStreet&#39;s Feuerstein says Halozyme selective in data read-out from mid-stage pancreatic cancer study of PEGPH20\" data-tweet=\"$HALO - TheStreet&#39;s Feuerstein says Halozyme selective in data read-out from mid-stage pancreatic cancer study of PEGPH20 https://seekingalpha.com/news/3233650-thestreets-feuerstein-says-halozyme-selective-in-data-read-out-from-mid-stage-pancreatic?source=tweet\" data-url=\"https://seekingalpha.com/news/3233650-thestreets-feuerstein-says-halozyme-selective-in-data-read-out-from-mid-stage-pancreatic\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:47 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>26&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233653\" data-ts=\"1483627477\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CBL\" target=\"_blank\">CBL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233653-mall-players-down-on-retail-malaise\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mall players down on retail malaise</a></h4><ul><li><a href=\"https://seekingalpha.com/news/3233537-retail-names-reeling-warnings-macys-kohls\" target=\"_blank\">Where to start?</a> Macy's last night cut guidance, and set big job cuts and store closings. Kohl's cut estimates. Sears one day ago announced a few store closings, and this morning <a href=\"https://seekingalpha.com/pr/16706368-sears-holdings-announces-steps-enhance-liquidity-stabilize-operating-performance\" target=\"_blank\">announced 150 more</a>.</li><li>CBL &amp; Associates (<a href='https://seekingalpha.com/symbol/CBL' title='CBL & Associates Properties, Inc.'>CBL</a> <font color='red'>-3.3%</font>), PREIT (<a href='https://seekingalpha.com/symbol/PEI' title='Pennsylvania Real Estate Investment Trust'>PEI</a> <font color='red'>-3.6%</font>), DDR (DDR <font color='red'>-1.1%</font>), Taubman (<a href='https://seekingalpha.com/symbol/TCO' title='Taubman Centers, Inc.'>TCO</a> <font color='red'>-1.9%</font>), Weingarten (<a href='https://seekingalpha.com/symbol/WRI' title='Weingarten Realty Investors'>WRI</a> <font color='red'>-1.4%</font>), Kimco (<a href='https://seekingalpha.com/symbol/KIM' title='Kimco Realty Corporation'>KIM</a> <font color='red'>-1.1%</font>), Retail Opportunity (<a href='https://seekingalpha.com/symbol/ROIC' title='Retail Opportunity Investments Corp.'>ROIC</a> <font color='red'>-1.2%</font>), Federal Realty (<a href='https://seekingalpha.com/symbol/FRT' title='Federal Realty Investment Trust'>FRT</a> <font color='red'>-1.3%</font>)</li><li>\"A\" players are being hit as well ... Simon Property (<a href='https://seekingalpha.com/symbol/SPG' title='Simon Property Group, Inc.'>SPG</a> <font color='red'>-2.9%</font>), General Growth (GGP <font color='red'>-3%</font>), Macerich (<a href='https://seekingalpha.com/symbol/MAC' title='Macerich Co.'>MAC</a> <font color='red'>-2.7%</font>), Brixmor (<a href='https://seekingalpha.com/symbol/BRX' title='Brixmor Property Group Inc.'>BRX</a> <font color='red'>-1.2%</font>).</li><li>Previously: <a href=\"https://seekingalpha.com/news/3233647-preit-demand-macys-spaces-robust\" target=\"_blank\">PREIT: \"Demand for Macy's spaces is robust\"</a> (Jan. 5)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3233521-cbl-announces-plans-redevelop-4-macys-locations\" target=\"_blank\">CBL announces plans to redevelop 4 Macy's locations</a> (Jan. 4)</li></ul><div class=\"tiny-share-widget\" data-id=\"3233653\" data-linked=\"Mall players down on retail malaise\" data-tweet=\"$CBL $CBL $PEI - Mall players down on retail malaise https://seekingalpha.com/news/3233653-mall-players-down-on-retail-malaise?source=tweet\" data-url=\"https://seekingalpha.com/news/3233653-mall-players-down-on-retail-malaise\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:44 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233644\" data-ts=\"1483626022\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALXN\" target=\"_blank\">ALXN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233644-alexion-files-q3-financials-no-restatement-needed-shares-ahead-5-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Alexion files Q3 financials; no restatement needed; shares ahead 5% premarket</a></h4><ul><li>Alexion Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ALXN' title='Alexion Pharmaceuticals, Inc.'>ALXN</a>) is up&nbsp;<font color='green'>5%</font>&nbsp;premarket on increased volume on the <a href=\"https://seekingalpha.com/pr/16705495-alexion-pharmaceuticals-files-form-10-q-third-quarter-2016\" target=\"_blank\">news </a>that it has filed its 10-Q for the third quarter of 2016. The company delayed filing while its Audit and Finance Committee investigated allegations from a former employee concerning its sales practices related to Soliris (eculizumab). The Committee determined that no restatement is necessary.</li></ul><div class=\"tiny-share-widget\" data-id=\"3233644\" data-linked=\"Alexion files Q3 financials; no restatement needed; shares ahead 5% premarket\" data-tweet=\"$ALXN - Alexion files Q3 financials; no restatement needed; shares ahead 5% premarket https://seekingalpha.com/news/3233644-alexion-files-q3-financials-no-restatement-needed-shares-ahead-5-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3233644-alexion-files-q3-financials-no-restatement-needed-shares-ahead-5-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:20 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233640\" data-ts=\"1483625545\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233640-premarket-gainers-losers-of-9-10\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers / Losers as of 9:10 am</a></h4><ul> <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/PIRS' title='Pieris Pharmaceuticals, Inc.'>PIRS</a> <font color='green'>+32%</font>. <a href='https://seekingalpha.com/symbol/CTIC' title='CTI BioPharma Corp.'>CTIC</a> <font color='green'>+24%</font>. <a href='https://seekingalpha.com/symbol/CEB' title='CEB Inc.'>CEB</a> <font color='green'>+21%</font>. <a href='https://seekingalpha.com/symbol/KOOL' title='Cesca Therapeutics Inc'>KOOL</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/HALO' title='Halozyme Therapeutics, Inc.'>HALO</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/GNCA' title='Genocea Biosciences, Inc.'>GNCA</a> <font color='green'>+13%</font>. ETRM <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/EVOK' title='Evoke Pharma, Inc.'>EVOK</a> <font color='green'>+12%</font>. SHLD <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/EXAS' title='EXACT Sciences Corporation'>EXAS</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/AG' title='First Majestic Silver Corp.'>AG</a> <font color='green'>+5%</font>. <a href='https://seekingalpha.com/symbol/IDXG' title='Interpace Diagnostics Group, Inc.'>IDXG</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/ALXN' title='Alexion Pharmaceuticals, Inc.'>ALXN</a> <font color='green'>+5%</font>.</li> <li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/AEZS' title='AEterna Zentaris, Inc.'>AEZS</a> <font color='red'>-34%</font>. <a href='https://seekingalpha.com/symbol/KSS' title='Kohl&#39;s Corporation'>KSS</a> <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/M' title='Macy&#39;s Inc.'>M</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/HRTX' title='Heron Therapeutics, Inc.'>HRTX</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/BCEI' title='Bonanza Creek Energy'>BCEI</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/OREX' title='Orexigen Therapeutics, Inc.'>OREX</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/KNOP' title='KNOT Offshore Partners LP'>KNOP</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/JWN' title='Nordstrom Inc.'>JWN</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/IT' title='Gartner Inc.'>IT</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/HLX' title='Helix Energy Solutions Group, Inc.'>HLX</a> <font color='red'>-6%</font>. URRE <font color='red'>-5%</font>. <a href='https://seekingalpha.com/symbol/JCP' title='J.C. Penney Company Inc.'>JCP</a> <font color='red'>-6%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3233640\" data-linked=\"Premarket Gainers / Losers as of 9:10 am\" data-tweet=\"$PIRS $CTIC $CEB - Premarket Gainers / Losers as of 9:10 am https://seekingalpha.com/news/3233640-premarket-gainers-losers-of-9-10?source=tweet\" data-url=\"https://seekingalpha.com/news/3233640-premarket-gainers-losers-of-9-10\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:12 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233639\" data-ts=\"1483625426\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233639-treasury-yields-lower-after-mixed-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Treasury yields lower after mixed data</a></h4><ul><li>The <a href=\"https://seekingalpha.com/news/3233606-u-s-economy-added-153k-jobs-december\" target=\"_blank\">ADP reported 153K</a> private-sector jobs added in December - that's down from 216K in November, and lower than expectations for 172K.</li><li>In the 12 months prior to December, ADP job gains averaged 187K.</li><li>Initial jobless claims, however, paint a far stronger picture, <a href=\"https://seekingalpha.com/news/3233615-jobless-claim-tumbles-1-1-2-month-low\" target=\"_blank\">falling 28K to 235K</a> - the lowest since 1973. It was a holiday week, so the print is likely being brushed off by traders.</li><li>The 10-year Treasury yield is lower by 2.4 basis points to 2.417%. <a href='https://seekingalpha.com/symbol/TLT' title='iShares 20+ Year Treasury Bond ETF'>TLT</a>&nbsp;<font color='green'>+0.4%</font>, <a href='https://seekingalpha.com/symbol/TBT' title='ProShares UltraShort 20+ Year Treasury ETF'>TBT</a>&nbsp;<font color='red'>-0.8%</font></li><li>ETFs: <a href='https://seekingalpha.com/symbol/TBT' title='ProShares UltraShort 20+ Year Treasury ETF'>TBT</a>, <a href='https://seekingalpha.com/symbol/TLT' title='iShares 20+ Year Treasury Bond ETF'>TLT</a>, <a href='https://seekingalpha.com/symbol/TMV' title='Direxion Daily 20+ Year Treasury Bear 3x Shares ETF'>TMV</a>, <a href='https://seekingalpha.com/symbol/TBF' title='ProShares Short 20+ Year Treasury ETF'>TBF</a>, <a href='https://seekingalpha.com/symbol/EDV' title='Vanguard Extended Duration Treasury ETF'>EDV</a>, <a href='https://seekingalpha.com/symbol/TMF' title='Direxion Daily 30-Year Treasury Bull 3x Shares ETF'>TMF</a>, <a href='https://seekingalpha.com/symbol/TTT' title='ProShares UltraPro Short 20+ Year Treasury ETF'>TTT</a>, <a href='https://seekingalpha.com/symbol/ZROZ' title='PIMCO 25+ Year Zero Coupon U.S. Treasury Index ETF'>ZROZ</a>, <a href='https://seekingalpha.com/symbol/VGLT' title='Vanguard Long-Term Government Bond Index ETF'>VGLT</a>, <a href='https://seekingalpha.com/symbol/TLH' title='iShares 10-20 Year Treasury Bond ETF'>TLH</a>, <a href='https://seekingalpha.com/symbol/UBT' title='ProShares Ultra 20+ Year Treasury ETF'>UBT</a>, <a href='https://seekingalpha.com/symbol/DLBS' title='iPath U.S. Treasury Long Bond Bear ETN'>DLBS</a>, <a href='https://seekingalpha.com/symbol/TLO' title='SPDR Barclays Long Term Treasury ETF'>TLO</a>, <a href='https://seekingalpha.com/symbol/VUSTX' title='Vanguard Long Term Treasury Fund Inv'>VUSTX</a>, <a href='https://seekingalpha.com/symbol/DLBL' title='iPath U.S. Treasury Long Bond Bull ETN'>DLBL</a>, <a href='https://seekingalpha.com/symbol/TYBS' title='Direxion Daily 20+ Year Treasury Bear 1x Shares ETF'>TYBS</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3233639\" data-linked=\"Treasury yields lower after mixed data\" data-tweet=\"$TLT $TBT $TMV - Treasury yields lower after mixed data https://seekingalpha.com/news/3233639-treasury-yields-lower-after-mixed-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3233639-treasury-yields-lower-after-mixed-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:10 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233638\" data-ts=\"1483625339\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OBE\" target=\"_blank\">OBE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233638-penn-west-raises-2017-capex-budget-hendry-to-replace-dyck-cfo\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Penn West raises 2017 capex budget; Hendry to replace Dyck as CFO</a></h4><ul>     <li>Penn West Petroleum (PWE) <font color='green'>+3.2%</font> premarket after saying it plans to <a href=\"https://seekingalpha.com/pr/16705757-penn-west-announces-2017-capital-budget-senior-management-changes\" target=\"_blank\">raise its 2017 capital budget to C$180M</a> from C$150M last year while anticipating a 15% increase in production from core areas.</li>     <li>PWE expects to deliver full-year production of 27K-29K boe/day, roughly two-thirds in liquids, with 2017 exit rates 15% over Q4 2016 production volumes in key development areas.</li>     <li>The company had forecast 2016 capital spending of C$90M and 10% core production growth in 2017.</li>     <li>Also, PWE says CFO David Dyck and senior production VP Gregg Gegunde will leave the company, effective immediately; David Hendry, VP of finance for the last two years and former VP of finance at Talisman energy, will become CFO.</li></ul><div class=\"tiny-share-widget\" data-id=\"3233638\" data-linked=\"Penn West raises 2017 capex budget; Hendry to replace Dyck as CFO\" data-tweet=\"$OBE - Penn West raises 2017 capex budget; Hendry to replace Dyck as CFO https://seekingalpha.com/news/3233638-penn-west-raises-2017-capex-budget-hendry-to-replace-dyck-cfo?source=tweet\" data-url=\"https://seekingalpha.com/news/3233638-penn-west-raises-2017-capex-budget-hendry-to-replace-dyck-cfo\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:08 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>55&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233633\" data-ts=\"1483624977\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SGMO\" target=\"_blank\">SGMO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233633-fda-oks-sangamos-ind-for-gene-therapy-candidate-for-hemophilia-shares-ahead-7-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA OKs Sangamo&#39;s IND for gene therapy candidate for hemophilia A; shares ahead 7% premarket</a></h4><ul><li>The FDA <a href=\"https://seekingalpha.com/pr/16705991-sangamo-biosciences-announces-fda-clearance-investigational-new-drug-application-sbminus-525\" target=\"_blank\">clears </a>Sangamo BioSciences' (NASDAQ:<a href='https://seekingalpha.com/symbol/SGMO' title='Sangamo Therapeutics, Inc.'>SGMO</a>) Investigational New Drug &#40;IND&#41; application for gene therapy candidate SB-525 for the treatment of hemophilia A. Phase 1 development to assess safety, tolerability and potential efficacy may now proceed.</li><li><a href=\"http://www.sangamo.com/pipeline/hemophilia.html\" target=\"_blank\">SB-525</a> uses an adeno-associated virus (AAV2/6) complimentary DNA (cDNA) human Factor 8 construct driven by the company's proprietary synthetic liver-specific promoter. Sangamo says preclinical studies showed it to be significantly more potent than other AAV-based cDNA constructs currently being investigated for the treatment of hemophilia A.</li><li>Shares are up&nbsp;<font color='green'>7%&nbsp;</font>premarket on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3233633\" data-linked=\"FDA OKs Sangamo&#39;s IND for gene therapy candidate for hemophilia A; shares ahead 7% premarket\" data-tweet=\"$SGMO - FDA OKs Sangamo&#39;s IND for gene therapy candidate for hemophilia A; shares ahead 7% premarket https://seekingalpha.com/news/3233633-fda-oks-sangamos-ind-for-gene-therapy-candidate-for-hemophilia-shares-ahead-7-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3233633-fda-oks-sangamos-ind-for-gene-therapy-candidate-for-hemophilia-shares-ahead-7-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:02 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233630\" data-ts=\"1483624642\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KRC\" target=\"_blank\">KRC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233630-kilroy-realty-down-1_5-after-share-sale\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Kilroy Realty down 1.5% after share sale</a></h4><ul><li>Kilroy (NYSE:<a href='https://seekingalpha.com/symbol/KRC' title='Kilroy Realty Corporation'>KRC</a>) sold 3.85M shares <a href=\"https://seekingalpha.com/pr/16705576-kilroy-realty-corporation-prices-offering-common-stock\" target=\"_blank\">at $72.75 each</a>. The underwriters have the option to buy another 577.5K shares at that price.</li><li>The stock's&nbsp;<font color='red'>lower by 1.5%</font>&nbsp;premarket to $73.20.</li></ul><div class=\"tiny-share-widget\" data-id=\"3233630\" data-linked=\"Kilroy Realty down 1.5% after share sale\" data-tweet=\"$KRC - Kilroy Realty down 1.5% after share sale https://seekingalpha.com/news/3233630-kilroy-realty-down-1_5-after-share-sale?source=tweet\" data-url=\"https://seekingalpha.com/news/3233630-kilroy-realty-down-1_5-after-share-sale\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:57 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233628\" data-ts=\"1483624521\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BKS\" target=\"_blank\">BKS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233628-holiday-sales-fall-barnes-noble\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Holiday sales fall at Barnes &amp; Noble</a></h4><ul> <li>Barnes &amp; Noble (NYSE:<a href='https://seekingalpha.com/symbol/BKS' title='Barnes & Noble Inc'>BKS</a>) discloses that       comparable store sales sank 9.1% for the nine-week holiday period       ending December 31, 2016.</li>     <li>Online sales were up ~2% for       the holiday period.</li>     <li>The company say the sales decrease was largely due to lower traffic and a tough comparison to last year when a best-selling album       by Adele was a boost.</li>     <li>B&amp;N&nbsp;still expects to exceed last year&rsquo;s operating profit on strong expense       management.</li><li>BKS  <font color='green'>+5.70%</font> premarket to  $12.05.</li><li>Source: <a href=\"https://seekingalpha.com/pr/16706135-barnes-and-noble-reports-holiday-comparable-store-sales\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3233628\" data-linked=\"Holiday sales fall at Barnes &amp; Noble\" data-tweet=\"$BKS - Holiday sales fall at Barnes &amp; Noble https://seekingalpha.com/news/3233628-holiday-sales-fall-barnes-noble?source=tweet\" data-url=\"https://seekingalpha.com/news/3233628-holiday-sales-fall-barnes-noble\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:55 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233623\" data-ts=\"1483623721\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/STZ\" target=\"_blank\">STZ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233623-on-constellation-brands-fq3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More on Constellation Brands&#39; FQ3</a></h4><ul>     <li>Constellation Brands (NYSE:<a href='https://seekingalpha.com/symbol/STZ' title='Constellation Brands, Inc.'>STZ</a>) reports organic net sales rose 7% to $1.75B in <a href=\"http://www.cbrands.com/news-media/constellation-brands-reports-third-quarter-fiscal-2017-results\" target=\"_blank\">FQ3</a>.</li>     <li>Beer segment sales expanded 16% to $964.6M driven primarily by volume growth and favorable pricing, and the acquisition benefit from Ballast Point.</li>     <li>Wine and spirits sales increased 5% to $845.9M due to&nbsp;acquisition benefit from The Prisoner wine brands and favorable mix</li>     <li>Adjusted gross margin rate improved 250 bps to 48.8%.</li>     <li>Adjusted operating margin rate grew 40 bps to 29.4%.</li>     <li>Shipment volume: Beer: 57.7M (+12.3%);&nbsp;Wine and spirits: 18.3M (-0.5%).</li>     <li><b>FY2017 Guidance</b>: Beer segment sales: +16% to +17%; Wine &amp; Spirits segment sales:&nbsp;mid single-digit growth; Beer operating income: high teens growth; Wine &amp; Spirits operating income:&nbsp;mid to high single-digit growth; Interest expense: $335M to $345M; Tax rate: ~27%;&nbsp;Weighted average diluted shares outstanding: ~204.5M; Diluted EPS: $7.55 to $7.65; Adjusted diluted EPS: $6.55 to $6.65; Free cash flow: $575M to $675M; Operating cash flow: $1.4B to $1.6B; Capex: ~$825M to $925M.</li>     <li>STZ&nbsp;<font color='red'>-2.53%</font>&nbsp;premarket.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3233623\" data-linked=\"More on Constellation Brands&#39; FQ3\" data-tweet=\"$STZ - More on Constellation Brands&#39; FQ3 https://seekingalpha.com/news/3233623-on-constellation-brands-fq3?source=tweet\" data-url=\"https://seekingalpha.com/news/3233623-on-constellation-brands-fq3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:42 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>24&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233620\" data-ts=\"1483623374\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TRV\" target=\"_blank\">TRV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233620-travelers-down-1_5-on-morgan-stanley-downgrade-progressive-boosted\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Travelers down 1.5% on Morgan Stanley downgrade; Progressive boosted</a></h4><ul><li>Citing concerns over lower reserve releases, auto margin pressure, and the stock's premium valuation, analyst Kai Pan downgrades Travelers (NYSE:<a href='https://seekingalpha.com/symbol/TRV' title='The Travelers Companies, Inc.'>TRV</a>) to Underweight from Equalweight. Shares are&nbsp;<font color='red'>lower by 1.5%</font>&nbsp;in thin premarket action.</li><li>Alongside, he upgrades Progressive (NYSE:<a href='https://seekingalpha.com/symbol/PGR' title='Progressive Corporation'>PGR</a>) to Equalweight from Underweight, noting the company is likely to see bigger benefits from lower taxes and rising yield than its peers.</li><li>For the P&amp;C sector as a whole, Pan boosts price targets by 6%, though reminding some potential upside has been priced in since the election. Chubb (NYSE:<a href='https://seekingalpha.com/symbol/CB' title='Chubb Ltd'>CB</a>) and XL Group (NYSE:<a href='https://seekingalpha.com/symbol/XL' title='XL Group plc'>XL</a>) remain top picks.</li></ul><div class=\"tiny-share-widget\" data-id=\"3233620\" data-linked=\"Travelers down 1.5% on Morgan Stanley downgrade; Progressive boosted\" data-tweet=\"$TRV $TRV $PGR - Travelers down 1.5% on Morgan Stanley downgrade; Progressive boosted https://seekingalpha.com/news/3233620-travelers-down-1_5-on-morgan-stanley-downgrade-progressive-boosted?source=tweet\" data-url=\"https://seekingalpha.com/news/3233620-travelers-down-1_5-on-morgan-stanley-downgrade-progressive-boosted\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:36 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233619\" data-ts=\"1483623235\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CMG\" target=\"_blank\">CMG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233619-chipotle-lands-wedbush-upgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Chipotle lands Wedbush upgrade</a></h4><ul> <li>Chipotle (NYSE:<a href='https://seekingalpha.com/symbol/CMG' title='Chipotle Mexican Grill, Inc.'>CMG</a>) shook off one of its bearish calls this morning when Wedbush moved to a Neutral stance from Underperform. The restaurant stock still has seven Wall Street firms with <a href=\"https://www.marketbeat.com/stocks/NYSE/CMG/\" target=\"_blank\">Sell ratings</a> on the books and plenty of <a href=\"https://seekingalpha.com/symbol/CMG/focus\" target=\"_blank\">SA contributers</a> taking a whack at it.</li> <li>The investment firm's price target of $400 implies 5% upside.</li> <li>Shares of CMG are <font color='green'>up 0.82%</font> premarket to $385.00.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3233619\" data-linked=\"Chipotle lands Wedbush upgrade\" data-tweet=\"$CMG - Chipotle lands Wedbush upgrade https://seekingalpha.com/news/3233619-chipotle-lands-wedbush-upgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3233619-chipotle-lands-wedbush-upgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:33 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233613\" data-ts=\"1483622541\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BTCS\" target=\"_blank\">BTCS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233613-bitcoin-rally-takes-breather\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bitcoin rally takes a breather</a></h4><ul><li>The big bull market in Bitcoin (<a href='https://seekingalpha.com/symbol/BTCS' title='BTCS Inc.'>OTCQB:BTCS</a>, <a href='https://seekingalpha.com/symbol/COIN' title='Winklevoss Bitcoin Trust ETF'>COIN</a>) reverses <a href=\"http://bitcoinity.org/markets\" target=\"_blank\">sharply this morning</a>, with the crypto-currency&nbsp;<font color='red'>down nearly 18%</font>&nbsp;in just the last hour and now selling at $886. Earlier today, it was changing hands at nearly $1,115.</li><li>The move comes as China's yuan (<a href='https://seekingalpha.com/symbol/CYB' title='WisdomTree Chinese Yuan ETF'>CYB</a>, <a href='https://seekingalpha.com/symbol/CNY' title='Market Vectors Chinese Renminbi/USD ETN'>CNY</a>, <a href='https://seekingalpha.com/symbol/FXCH' title='Invesco CurrencyShares Chinese Renminbi Trust ETF'>FXCH</a>) overnight surged <a href=\"http://www.cnbc.com/2017/01/04/chinas-offshore-yuan-surges-most-against-dollar-in-a-year.html\" target=\"_blank\">the most vs. the greenback</a> in a year.</li></ul><div class=\"tiny-share-widget\" data-id=\"3233613\" data-linked=\"Bitcoin rally takes a breather\" data-tweet=\"$BTCS $BTCS $COIN - Bitcoin rally takes a breather https://seekingalpha.com/news/3233613-bitcoin-rally-takes-breather?source=tweet\" data-url=\"https://seekingalpha.com/news/3233613-bitcoin-rally-takes-breather\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:22 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233609\" data-ts=\"1483622380\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HALO\" target=\"_blank\">HALO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233609-halozymes-lead-product-candidate-shows-positive-effect-in-mid-stage-pancreatic-cancer-study\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Halozyme&#39;s lead product candidate shows positive effect in mid-stage pancreatic cancer study; shares ahead 25% premarket</a></h4><ul><li>Halozyme Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/HALO' title='Halozyme Therapeutics, Inc.'>HALO</a>) is up&nbsp;<font color='green'>25%</font>&nbsp;premarket on robust volume in response to its <a href=\"https://www.sec.gov/Archives/edgar/data/1159036/000115903617000002/a01_05x2017halozyme202news.htm\" target=\"_blank\">announcement </a>of positive results from a Phase 2 clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT01839487?term=halo+202&amp;rank=1\" target=\"_blank\">HALO-202</a>, assessing lead product candidate PEGPH20 combined with Celgene's (NASDAQ:<a href='https://seekingalpha.com/symbol/CELG' title='Celgene Corporation'>CELG</a>) <a href=\"http://www.abraxane.com/hcp/?b=1&amp;gclid=COfs5pWJq9ECFVSewAod6xQFzA\" target=\"_blank\">ABRAXANE </a>(paclitaxel protein-bound particles for injectable suspension)(albumin-bound) and the chemo agent gemcitabine for the treatment of stage IV (metastatic) pancreatic cancer patients.</li><li>Subjects with high levels of hyaluronan (a chain of natural sugars that builds up around cancer cells inhibiting the effectiveness of cancer-killing therapies) who received the PEGPH20 combination experienced a statistically significant increase in progression-free survival compared to those receiving ABRAXANE and gemcitabine alone (8.6 months versus 4.5 months).</li><li>A Phase 3 study, <a href=\"https://clinicaltrials.gov/ct2/show/NCT02715804?term=NCT02715804&amp;rank=1\" target=\"_blank\">HALO-301</a>, assessing the combination is in process. According to ClinicalTrials.gov, the estimated final data collection date for the primary endpoint is October 2018.</li><li><a href=\"http://www.halozyme.com/technology-and-products/product-candidate/pegph20/default.aspx\" target=\"_blank\">PEGPH20</a>&nbsp;is an investigational drug administered intravenously that temporarily degrades hyaluronan.</li></ul><div class=\"tiny-share-widget\" data-id=\"3233609\" data-linked=\"Halozyme&#39;s lead product candidate shows positive effect in mid-stage pancreatic cancer study; shares ahead 25% premarket\" data-tweet=\"$HALO $HALO $CELG - Halozyme&#39;s lead product candidate shows positive effect in mid-stage pancreatic cancer study; shares ahead 25% premarket https://seekingalpha.com/news/3233609-halozymes-lead-product-candidate-shows-positive-effect-in-mid-stage-pancreatic-cancer-study?source=tweet\" data-url=\"https://seekingalpha.com/news/3233609-halozymes-lead-product-candidate-shows-positive-effect-in-mid-stage-pancreatic-cancer-study\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:19 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233608\" data-ts=\"1483622341\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TWLO\" target=\"_blank\">TWLO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233608-pacific-crest-securities-upgrades-twilio-to-overweight\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pacific Crest Securities upgrades Twilio to Overweight</a></h4><ul><li>From Sector Weight prior on <a href=\"http://www.cnbc.com/2017/01/05/early-movers-m-kss-alxn-googl-wba-myl-ma-more.html\" target=\"_blank\">\"underappreciated growth potential\"</a>&nbsp;intrinsic of a usage-based model alike that employed by Amazon Web Services.</li><li>Target on Twilio (NYSE:<a href='https://seekingalpha.com/symbol/TWLO' title='Twilio'>TWLO</a>) shares, which are to $28.50 pre-market on a&nbsp;<font color='green'>3.6% gain</font>, <a href=\"https://www.benzinga.com/news/17/01/8870700/pacific-crest-upgrades-twilio-to-overweight-announces-36-00-target\" target=\"_blank\">set at $36</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3233608\" data-linked=\"Pacific Crest Securities upgrades Twilio to Overweight\" data-tweet=\"$TWLO - Pacific Crest Securities upgrades Twilio to Overweight https://seekingalpha.com/news/3233608-pacific-crest-securities-upgrades-twilio-to-overweight?source=tweet\" data-url=\"https://seekingalpha.com/news/3233608-pacific-crest-securities-upgrades-twilio-to-overweight\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:19 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233603\" data-ts=\"1483621667\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SWK\" target=\"_blank\">SWK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233603-sears-unloads-craftsman-to-stanley-black-decker\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sears unloads Craftsman to Stanley Black &amp; Decker</a></h4><ul>     <li>Stanely Black &amp; Decker (NYSE:<a href='https://seekingalpha.com/symbol/SWK' title='Stanley Black & Decker, Inc.'>SWK</a>) acquires the well-known Craftsman brand from Sears Holdings (SHLD) for $525M to be paid at closing.</li>     <li>Sears will also take in $250M after the third year and receive annual payments on new Craftsman sales.</li>     <li>Sears will continue to sell Craftsman products under a perpetual license.</li>     <li>Stanley Black &amp; Decker sees a significant accretion benefit from the transaction. The company has been identified for quite a while as the likely winning bidder for Craftsman.</li><li>The deal has already been approved by both boards.</li>     <li>SWK  <font color='green'>+0.13%</font> premarket to  $116.63. SHLD&nbsp;<font color='green'>+3.57%</font>&nbsp;to $10.73.</li>          <li>Source: <a href=\"https://seekingalpha.com/pr/16705896-stanley-black-and-decker-reaches-agreement-purchase-craftsman-brand-sears-holdings\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3233603\" data-linked=\"Sears unloads Craftsman to Stanley Black &amp; Decker\" data-tweet=\"$SWK $SWK $SHLDQ - Sears unloads Craftsman to Stanley Black &amp; Decker https://seekingalpha.com/news/3233603-sears-unloads-craftsman-to-stanley-black-decker?source=tweet\" data-url=\"https://seekingalpha.com/news/3233603-sears-unloads-craftsman-to-stanley-black-decker\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:07 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>82&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233598\" data-ts=\"1483620936\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LB\" target=\"_blank\">LB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233598-l-brands-updates-on-sales-and-margins\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">L Brands updates on sales and margins</a></h4><ul> <li>L Brands (NYSE:<a href='https://seekingalpha.com/symbol/LB' title='L Brands, Inc.'>LB</a>) <a href=\"https://seekingalpha.com/pr/16705861-l-brands-reports-december-2016-sales-updates-fourth-quarter-earnings-guidance\" target=\"_blank\">reports</a> sales increased 1% during December to $2.415B.</li> <li>Comparable sales trailed off 1% during the period vs. +1.5% expected, dragged down by a 4% comp decline at Victoria's Secret.</li> <li>L Brands now expects Q4 EPS to fall in the low end of its $1.85 to $2.00 range. On a prerecorded call (available at 1-866-639-7583), L Brands management warned of a steep drop in merchandise margin rates and said January comparable sales are trending flat.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3233105-retail-sector-watch-preannouncements\" target=\"_blank\">Retail sector on watch for preannouncements</a> (Jan. 3)</li>  <li>LB <font color='red'>-4.96%</font> premarket to $64.00.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3233598\" data-linked=\"L Brands updates on sales and margins\" data-tweet=\"$LB - L Brands updates on sales and margins https://seekingalpha.com/news/3233598-l-brands-updates-on-sales-and-margins?source=tweet\" data-url=\"https://seekingalpha.com/news/3233598-l-brands-updates-on-sales-and-margins\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:55 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233592\" data-ts=\"1483620280\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SYN\" target=\"_blank\">SYN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233592-synthetic-bios-co-lead-product-candidate-successful-in-mid-stage-study-shares-ahead-25\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Synthetic Bio&#39;s co-lead product candidate successful in mid-stage study; shares ahead 25% premarket</a></h4><ul><li>Synthetic Biologics (NYSEMKT:<a href='https://seekingalpha.com/symbol/SYN' title='Synthetic Biologics, Inc.'>SYN</a>) is up&nbsp;<font color='green'>25%</font>&nbsp;premarket on average volume in response to its <a href=\"https://www.sec.gov/Archives/edgar/data/894158/000114420417000723/v456270_ex99-1.htm\" target=\"_blank\">announcement </a>of positive results from a 412-subject Phase 2b clinical trial assessing co-lead product candidate SYN-004 (ribaxamase) for reducing <em>Clostridium difficile</em> (<em>C. diff</em>) infections.</li><li>On a preliminary basis, patients receiving SYN-004 experienced a 71.4% relative risk reduction (p=0.045) in the rate of <em>C. diff</em> infection compared to placebo (two cases versus seven cases).</li><li>The company intends to advance SYN-004 into Phase 3 development.</li><li><a href=\"http://www.syntheticbiologics.com/product-pipeline/microbiome-focused-pipeline/syn-004-ribaxamase\" target=\"_blank\">Ribaxamase </a>is a first-in-class oral enzyme designed to degrade certain IV beta-lactam antibiotics within the GI tract and maintain the natural balance of the gut microbiome.</li></ul><div class=\"tiny-share-widget\" data-id=\"3233592\" data-linked=\"Synthetic Bio&#39;s co-lead product candidate successful in mid-stage study; shares ahead 25% premarket\" data-tweet=\"$SYN - Synthetic Bio&#39;s co-lead product candidate successful in mid-stage study; shares ahead 25% premarket https://seekingalpha.com/news/3233592-synthetic-bios-co-lead-product-candidate-successful-in-mid-stage-study-shares-ahead-25?source=tweet\" data-url=\"https://seekingalpha.com/news/3233592-synthetic-bios-co-lead-product-candidate-successful-in-mid-stage-study-shares-ahead-25\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:44 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233585\" data-ts=\"1483619329\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GNCA\" target=\"_blank\">GNCA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233585-genoceas-lead-product-candidate-shows-positive-effect-in-mid-stage-study-shares-ahead-21\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Genocea&#39;s lead product candidate shows positive effect in mid-stage study; shares ahead 21% premarket</a></h4><ul><li>Thinly traded micro cap Genocea Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/GNCA' title='Genocea Biosciences, Inc.'>GNCA</a>) is up&nbsp;<font color='green'>21%</font>&nbsp;premarket on average volume in response to its <a href=\"https://www.sec.gov/Archives/edgar/data/1457612/000145761217000002/gnca0030036monthdata010520.htm\" target=\"_blank\">announcement </a>of positive results in a Phase 2b clinical trial assessing lead product candidate GEN-003 for the treatment of genital herpes infections.</li><li>An interim analysis showed treatment with GEN-003 reduced the rate of genital lesions 41% versus placebo during the six months following dosing (p&lt;0.05).</li><li>The data support the selection of the 60 microgram/antigen/50 microgram of adjuvant dose as the optimal dose for the planned Phase 3 program.</li><li><a href=\"http://www.genocea.com/pipeline/gen003-for-genital-herpes/\" target=\"_blank\">GEN-003</a> is a protein subunit T cell-enable therapeutic vaccine designed to reduce the duration and severity of clinical symptoms related to moderate-to-severe genital herpes and to control transmission of infection. It attacks the genital herpes virus by inducing both a T cell and B cell immune response via two antigens called ICP4 and gD2. Its action is enhanced by the use of a proprietary adjuvant called Matrix-M.</li><li>Management will host a conference call today at 9:00 am ET to discuss the results.</li></ul><div class=\"tiny-share-widget\" data-id=\"3233585\" data-linked=\"Genocea&#39;s lead product candidate shows positive effect in mid-stage study; shares ahead 21% premarket\" data-tweet=\"$GNCA - Genocea&#39;s lead product candidate shows positive effect in mid-stage study; shares ahead 21% premarket https://seekingalpha.com/news/3233585-genoceas-lead-product-candidate-shows-positive-effect-in-mid-stage-study-shares-ahead-21?source=tweet\" data-url=\"https://seekingalpha.com/news/3233585-genoceas-lead-product-candidate-shows-positive-effect-in-mid-stage-study-shares-ahead-21\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:28 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3233579\" data-ts=\"1483618368\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CEB\" target=\"_blank\">CEB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3233579-gartner-buying-ceb-for-2_6b\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gartner buying CEB for $2.6B</a></h4><ul><li>Under the terms of the agreement, <a href='https://seekingalpha.com/symbol/CEB' title='CEB Inc.'>CEB</a> shareholders will receive $54 in cash and 0.2284 shares of Gartner (NYSE:<a href='https://seekingalpha.com/symbol/IT' title='Gartner Inc.'>IT</a>) common stock for each share of CEB they own - a total of $77.25 per share, or&nbsp;<font color='green'>about 25% above</font>&nbsp;last night's close.</li><li>The deal will be immediately accretive to Gartner's adjusted EPS and should be double-digit percentage accretive in 2018.</li><li>The sale is expected to close in H1 of this year.</li><li>A <a href=\"http://www.investor.gartner.com\" target=\"_blank\">conference call</a> is set for 8:30 ET.</li></ul><div class=\"tiny-share-widget\" data-id=\"3233579\" data-linked=\"Gartner buying CEB for $2.6B\" data-tweet=\"$CEB $CEB $IT - Gartner buying CEB for $2.6B https://seekingalpha.com/news/3233579-gartner-buying-ceb-for-2_6b?source=tweet\" data-url=\"https://seekingalpha.com/news/3233579-gartner-buying-ceb-for-2_6b\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:12 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li>","count":71,"message":null,"success":true,"today":{"start":1576990800,"end":1577077199,"str":"Sunday, December 22, 2019"},"yesterday":{"start":1576904400,"end":1576990799}}